var title_f8_36_8768="Ureterouretostomy";
var content_f8_36_8768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Ureterouretostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 465px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts anastomosis of the spatulated ends of the proximal and distal portion of the ureter. The anastomosis is performed with an interrupted, absorbable suture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8768=[""].join("\n");
var outline_f8_36_8768=null;
var title_f8_36_8769="Papular xanthoma";
var content_f8_36_8769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Papular xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This healthy 11-year-old boy developed multiple yellow-red papules clustered on and around his nose. He has no mucous membrane lesions, and a lipid profile was normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8769=[""].join("\n");
var outline_f8_36_8769=null;
var title_f8_36_8770="CT spigelian hernia";
var content_f8_36_8770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spigelian hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Herniation of fat through a defect in the aponeurosis between the left rectus abdominis (white arrow) and the aponeurosis of the left transversus abdominis and internal oblique muscles. The lateral margin of the hernia sac is the external oblique muscle and fascia (yellow arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg, RL. Clinical Imaging: An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8770=[""].join("\n");
var outline_f8_36_8770=null;
var title_f8_36_8771="Parasternal short axis color Doppler";
var content_f8_36_8771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parasternal short axis view through the base of the heart with color flow Doppler imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 277px; height: 524px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal short axis view is recorded from the base of the heart. Color flow Doppler imaging during systole (panel A), demonstrates normal systolic flow from the right ventricular outflow tract (RVOT) to the main pulmonary artery (MPA). The flow signal is red in the proximal RVOT as it travels towards the transducer. As it moves at right angles to the interrogating beam the signal briefly disappears. When the flow turns away from the transducer and exits into the MPA it is coded blue. Imaging from short axis view through the base of the heart during diastole (panel B) shows diastolic flow signal (red) from pulmonic valve (PV) denoting trivial pulmonic regurgitation (PR) which is found in 90 percent of normals.",
"    <div class=\"footnotes\">",
"     Ao: aorta; RA: right atrium.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8771=[""].join("\n");
var outline_f8_36_8771=null;
var title_f8_36_8772="Incisions for skin sparing mastectomy";
var content_f8_36_8772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Incisions for skin sparing mastectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A variety of skin-sparing incisions have been described. Three incision types more frequently used include the (A) periareolar, (B) tennis racket, and (C) teardrop. Tennis racket or teardrop incisions are used to obtain better access to the axilla, especially if the patient has a small breast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Shaughnessy EA. Simple mastectomy. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8772=[""].join("\n");
var outline_f8_36_8772=null;
var title_f8_36_8773="Dihydroergotamine: Patient drug information";
var content_f8_36_8773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dihydroergotamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=see_link\">",
"     see \"Dihydroergotamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=see_link\">",
"     see \"Dihydroergotamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      D.H.E. 45&reg;;",
"     </li>",
"     <li>",
"      Migranal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Migranal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691956",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701953",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dihydroergotamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Heart disease, kidney disease, liver disease, poor blood flow, poor bowel blood flow, recent heart attack, bad infection, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703847",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken almotriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, or zolmitriptan in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken ergotamine or methysergide in the last 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you get more attacks the same day, do not use unless at least 6 hours have passed since your last shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose spray:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694903",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing by the nose. Prime pump by squeezing it 4 times. Breathe in 1 spray in each nostril. Wait 15 minutes. Breathe in 1 more spray in each nostril.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Once the nose spray is ready, throw away any part of the opened ampul not used after 8 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12383 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8773=[""].join("\n");
var outline_f8_36_8773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160464\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160465\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019271\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019273\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019272\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019277\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019278\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019280\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019275\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019276\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019281\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019282\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/13/15574?source=related_link\">",
"      Dihydroergotamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/3/44085?source=related_link\">",
"      Dihydroergotamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_36_8774="Antithrombin III: Drug information";
var content_f8_36_8774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antithrombin III: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/16/33028?source=see_link\">",
"    see \"Antithrombin III: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atryn&reg;;",
"     </li>",
"     <li>",
"      Thrombate III&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Antithrombin III NF;",
"     </li>",
"     <li>",
"      Thrombate III&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F135965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticoagulant;",
"     </li>",
"     <li>",
"      Blood Product Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F135933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antithrombin deficiency:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Atryn&reg;:",
"      </i>",
"     </b>",
"     Prophylaxis of thrombosis during surgical or obstetrical procedures:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing is individualized based on pretherapy antithrombin (AT) activity levels. Therapy should begin before delivery or ~24 hours prior to surgery to obtain target AT activity levels. Dosing should be targeted to keep levels between 80% to 120% of normal. Loading dose should be given as a 15-minute infusion, followed by maintenance dose as a continuous infusion. Doses may be calculated based on the following formulas:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Surgical patients (nonpregnant):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: [(100 - baseline AT activity level)",
"     <b>",
"      divided",
"     </b>",
"     by 2.3] x body weight (kg) = units of antithrombin required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance infusion: [(100 - baseline AT activity level)",
"     <b>",
"      divided",
"     </b>",
"     by 10.2] x body weight (kg) = units of antithrombin required/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Pregnant patients:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Pregnant women undergoing surgical procedures (other than a Cesarean section) should also be dosed according to the formula below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Loading dose: [(100 - baseline AT activity level)",
"     <b>",
"      divided",
"     </b>",
"     by 1.3] x body weight (kg) = units of antithrombin required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance infusion: [(100 - baseline AT activity level)",
"     <b>",
"      divided",
"     </b>",
"     by 5.4] x body weight (kg) = units of antithrombin required/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dosing adjustments: Adjustments should be made based on AT activity levels to maintain levels between 80% to 120% of normal. Surgery or delivery may rapidly decrease AT levels; check AT level just after surgery or delivery. The first AT level should be obtained 2 hours after initiation and adjusted as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AT activity level &lt;80%: Increase infusion rate by 30%; recheck AT level 2 hours after adjustment. Alternatively, an additional bolus dose (using loading dose formula) may be needed to rapidly restore AT levels. Calculate the additional bolus/loading dose using the last available AT activity result. After additional loading/bolus dose given, resume maintenance infusion at the same rate prior to bolus administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AT activity level 80% to 120%: No dosage adjustment needed; recheck AT level in 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AT activity level &gt;120%: Decrease infusion rate by 30%; recheck AT level 2 hours after adjustment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Thrombate III&reg;:",
"      </i>",
"     </b>",
"     Prophylaxis of thrombosis during surgical or obstetrical procedures or treatment of thromboembolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial loading dose: Dosing is individualized based on pretherapy antithrombin (AT) levels. The initial dose should raise AT levels to 120% and may be calculated based on the following formula:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     [(desired AT level % - baseline AT level %) x body weight (kg)]",
"     <b>",
"      divided",
"     </b>",
"     by 1.4 = units of antithrombin required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">",
"     For example, if a 70 kg adult patient had a baseline AT level of 57%, the initial dose would be",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;text-align:justify;\">",
"     [(120% - 57%) x 70] divided by 1.4  = 3150 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Maintenance dose: In general, subsequent dosing should be targeted to keep levels between 80% to 120% which may be achieved by administering 60% of the initial loading dose every 24 hours. Adjustments may be made by adjusting dose or interval. Maintain level within normal range for 2-8 days depending on type of procedure/situation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F135934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [human, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thrombate III&reg;: ~500 units [contains heparin; exact potency labeled on each vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [recombinant, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Atryn&reg;: ~1750 units [contains goat protein; exact potency labeled on each vial]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F135917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Administer intravenously.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ATryn&reg;: Infuse loading dose over 15 minutes, followed immediately by a continuous maintenance infusion. Administer reconstituted solution (without further dilution) or further diluted 100 units/mL solution. Filter during administration using an infusion set with a 0.22 micron in-line filter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombate III&reg;: Infuse over 10-20 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F135916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis (ATryn&reg;, Thrombate III&reg;) of thromboembolic events in patients with hereditary antithrombin (AT or AT-III) deficiency undergoing surgical or obstetrical procedures (eg, childbirth); treatment  (Thrombate III&reg;) of thromboembolism in patients with hereditary AT deficiency",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F135963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage (&ge;5%), hematoma (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzyme abnormalities (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hemarthrosis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infusion site reaction (&ge;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Bowel fullness, chest tightness, chills, cramps, dyspnea, fever, film over eye, foul taste, hives, lightheadedness, nausea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F135920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ATryn&reg;: Hypersensitivity to goat or goat milk proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombate III&reg;: There are no contraindications listed in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F135904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Atryn&reg;: Recombinant-derived product may cause severe hypersensitivity reactions, including anaphylaxis; monitor closely during infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections: Thrombate III&reg;: Product of human plasma; may potentially contain infectious agents which could transmit disease; screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Infections thought to be transmitted by this product should be reported to Talecris Biotherapeutics at 1-800-520-2807.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Atryn&reg;: Pharmacokinetics of the recombinant-derived product are influenced by pregnancy; distinct dosing recommendations are provided for pregnant women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Atryn&reg;: Not indicated for the treatment of thromboembolic events in hereditary antithrombin deficient patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunogenic potential: Atryn&reg;: Antibodies against the recombinant antithrombin protein (or goat-milk protein) may theoretically develop and lead to an immunological reaction. A postmarketing patient registry has been created to monitor for antibody development; physicians are encouraged to enroll by contacting Ovation Pharmaceuticals at 1-800-455-1141.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pharmacokinetic differences: Half-life and clearance differ significantly (~7-9 times) between the plasma-derived and the recombinant-derived product.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F135908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Antithrombin may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin in patients who have recently received treatment with antithrombin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2676560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Recent use/intake of herbs with anticoagulant or antiplatelet activity (including cat's claw, dong quai, evening primrose, garlic, ginkgo and ginseng) may increase the risk of bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (Thrombate III&reg;); C (ATryn&reg;) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F135922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ATryn&reg;: Adverse events were observed in some clinical studies, but not considered to be related to treatment. There are no adequate and well-controlled studies in pregnant women. An increased risk of fetal effects has not been observed in studies involving a limited number of pregnant women in their 3rd trimester. Pharmacokinetic studies in pregnant women using the recombinant product showed an increase in clearance and volume of distribution compared to nonpregnant patients. Therefore, distinct initial dosing recommendations are provided for pregnant women compared to nonpregnant patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombate III&reg;: Teratogenic effects were not observed in animal studies. Dosing recommendations do not differ for obstetric patients compared to nonpregnant patients.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F135940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9613966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ATryn&reg; has been detected in breast milk at concentrations of 1/50 to 1/100 of maternal serum concentrations (approximately equivalent to endogenous levels).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F135923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Thrombate III Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 unit (1): $4.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 unit (1): $4.38",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F135912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ATryn&reg;: Monitor AT activity level at baseline, 2 hours after initiation (and each dosage adjustment), and thereafter, at least once or twice daily when predictable levels achieved (between 80% and 120%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombate III&reg;: Initially, monitor AT at baseline, 20 minutes postinfusion (peak), 12 hours postinfusion, then preceding next infusion (trough level). Measure peak and trough AT levels with each subsequent dose until predictable levels achieved (between 80% and 120%). Some situations (eg, following surgery, hemorrhage or acute thrombosis, concurrent I.V. heparin administration), may require more frequent AT monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F135915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintain antithrombin level in plasma &gt;80%; plasma AT levels are ~60% lower near term infants than levels observed in adults; premature infants may have levels lower than other neonates.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F135924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anbin (ES);",
"     </li>",
"     <li>",
"      Anbinex (IL);",
"     </li>",
"     <li>",
"      Anthrobin P (JP);",
"     </li>",
"     <li>",
"      Antithrombin III (HK);",
"     </li>",
"     <li>",
"      Antithrombin III Immuno (HR, HU);",
"     </li>",
"     <li>",
"      Atenativ (DE, DK, ES, FI, HU, IT, NO, SE);",
"     </li>",
"     <li>",
"      Atenativ 500 (AT, CH, HN);",
"     </li>",
"     <li>",
"      Atend (MX);",
"     </li>",
"     <li>",
"      Athimbin HS 500 (AT);",
"     </li>",
"     <li>",
"      ATryn (CZ, EE, GB, GR, NL, PL, PT);",
"     </li>",
"     <li>",
"      Kybernin (ES, HR, HU);",
"     </li>",
"     <li>",
"      Kybernin P (AR, BR, ES, ID);",
"     </li>",
"     <li>",
"      Neuart (JP);",
"     </li>",
"     <li>",
"      Thrombotrol-VF (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F135903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antithrombin is the primary physiologic inhibitor of",
"     <i>",
"      in vivo",
"     </i>",
"     coagulation. It is an alpha",
"     <sub>",
"      2",
"     </sub>",
"     -globulin. Its principal actions are the inactivation of thrombin, plasmin, and other active serine proteases of coagulation, including factors IXa, Xa, XIa, and XIIa. The inactivation of proteases is a major step in the normal clotting process. The strong activation of clotting enzymes at the site of every bleeding injury facilitates fibrin formation and maintains normal hemostasis. Thrombosis in the circulation would be caused by active serine proteases if they were not inhibited by antithrombin after the localized clotting process.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F135919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Plasma derived (Thrombate III&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Half-life elimination: Biologic: 2.5 days (immunologic assay); 3.8 days (functional AT assay). Half-life may be decreased following surgery, with hemorrhage, acute thrombosis, and/or during heparin administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recombinant derived (Atryn&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Pregnant women: 14.3 L; Nonpregnant patients: 7.7 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Half-life elimination: 12-18 hours; surgery, childbirth hemorrhage, and/or concomitant heparin may shorten half-life",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Konkle BA, Bauer KA, Weinstein R, et al, &ldquo;Use of Recombinant Human Antithrombin in Patients With Congenital Antithrombin Deficiency Undergoing Surgical Procedures,&rdquo;",
"      <i>",
"       Transfusion",
"      </i>",
"      , 2003, 43(3):390-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/36/8774/abstract-text/12675726/pubmed\" id=\"12675726\" target=\"_blank\">",
"        12675726",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patnaik MM and Moll S, &ldquo;Inherited Antithrombin Deficiency: A Review,&rdquo;",
"      <i>",
"       Haemophilia",
"      </i>",
"      , 2008, 14(6):1229-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/36/8774/abstract-text/19141163/pubmed\" id=\"19141163\" target=\"_blank\">",
"        19141163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz RS, Bauer KA, Rosenberg RD, et al, &ldquo;Clinical Experience With Antithrombin III Concentrate in Treatment of Congenital and Acquired Deficiency of Antithrombin. The Antithrombin III Study Group,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1989, 87(3B):53S-60S.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tiede A, Tait RC, Shaffer DW, et al, &ldquo;Antithrombin Alfa in Hereditary Antithrombin Deficient Patients: A Phase 3 Study of Prophylactic Intravenous Administration in High Risk Situations,&rdquo;",
"      <i>",
"       Thromb Haemost",
"      </i>",
"      , 2008, 99(3):616-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/36/8774/abstract-text/18327412/pubmed\" id=\"18327412\" target=\"_blank\">",
"        18327412",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8849 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8774=[""].join("\n");
var outline_f8_36_8774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135930\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135931\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135965\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135933\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135934\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673198\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673199\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135914\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135900\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135917\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135916\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135963\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135920\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135904\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298762\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135908\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2676560\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135910\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135922\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135940\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613966\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135923\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322994\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135912\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135915\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135924\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135903\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135919\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8849|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/16/33028?source=related_link\">",
"      Antithrombin III: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_36_8775="Fungal rhinosinusitis";
var content_f8_36_8775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fungal rhinosinusitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Gary M Cox, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8775/contributors\">",
"     John R Perfect, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8775/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/36/8775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal rhinosinusitis encompasses a wide variety of fungal infections that range from merely irritating to rapidly fatal. Fungal colonization of the upper and lower airways is a common condition, since fungal spores are constantly inhaled into the sinuses and lungs. However, colonization is distinct from infection, and most colonized patients do not become ill with fungal infections. &ldquo;Fungal rhinosinusitis&rdquo; is the most appropriate term to describe fungal infection of the paranasal sinuses since concomitant involvement of the nasal cavity is seen in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fungal colonization, as well as the pathophysiology, clinical manifestation, diagnosis, and treatment of invasive fungal rhinosinusitis will be discussed here. An additional disorder, which involves a hypersensitivity response to colonizing fungi, is called allergic fungal rhinosinusitis and is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\", section on 'Allergic fungal rhinosinusitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNGAL COLONIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with anatomic abnormalities of the paranasal sinuses that impair drainage, such as nasal polyps or chronic inflammatory states, are vulnerable to fungal colonization in these areas. Areas of mucosal injury may cause pooling of mucus and subsequent colonization by fungus. However, these abnormalities are generally of no clinical importance. Aspergillus species are the most common colonizers of the sinuses, but many other species are also reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fungus balls",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fungal hyphae can become intertwined in dense collections and form fungus balls if there is obstruction of the paranasal sinuses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Patients usually present with symptoms of chronic rhinosinusitis and involvement of only one sinus cavity. Computed tomography (CT) often shows a metal-dense spot within the fungus ball, and this finding was reported in 72 percent of cases in one series of 160 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. There may be mild sclerosis of the surrounding bone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Surgery is required to correct the obstruction and to extract the fungus ball [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. Recurrence after surgical removal is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2\">",
"     2",
"    </a>",
"    ]. Glucocorticoids and antifungal agents do not offer clear benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INVASIVE FUNGAL SINUSITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The marked rise in the number of immunocompromised patients has led to an increase in unusual manifestations of aggressive fungal infections. Invasive rhinosinusitis is one such form of infection that appears to be increasing in frequency. Although invasive fungal rhinosinusitis can be seen in apparently immunocompetent patients, the majority of cases involve patients with some form of immunosuppression.",
"   </p>",
"   <p>",
"    Invasive fungal rhinosinusitis can be broadly classified as either acute or chronic [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute invasive fungal rhinosinusitis tends to occur in patients with profound immunosuppression, has a time course of days to a few weeks, and involves hyphal invasion of blood vessels with resulting tissue infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/1\">",
"     1",
"    </a>",
"    ]. In patients who are less immunocompromised, chronic invasive fungal rhinosinusitis occurs. This is a slowly destructive process with a typical time course of greater than 12 weeks; histopathology shows tissue destruction with a sparse inflammatory reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of immunosuppression in patients with all forms of invasive fungal rhinosinusitis are [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematologic malignancies",
"     </li>",
"     <li>",
"      Hematopoietic stem cell transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chemotherapy-induced neutropenia",
"     </li>",
"     <li>",
"      Solid organ transplantation",
"     </li>",
"     <li>",
"      Advanced HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Glucocorticoids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infection in immunocompromised patients may be attributable to invasion by fungi that have chronically colonized the sinuses or to inhalation of fungal spores. Many patients with invasive fungal rhinosinusitis have a history of chronic rhinosinusitis, and some have anatomic abnormalities of their sinuses that predispose to fungal colonization.",
"   </p>",
"   <p>",
"    Invasion of tissues adjacent to the sinuses occurs after the fungi establish local infection. The aggressiveness of tissue invasion may vary depending upon the underlying immune status of the host. Profoundly immunocompromised patients and those with poorly controlled diabetes can experience rapidly progressive disease over the course of a few hours, whereas the disease may be more indolent in patients with well-controlled diabetes or normal immune function. The spread of infection out of the sinuses is usually due to direct extension, but fungemia with metastatic spread can also occur.",
"   </p>",
"   <p>",
"    The fungi most often implicated in causing invasive rhinosinusitis are species of Aspergillus, Fusarium, the Mucorales, and dematiaceous (brown-black) molds [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/3,8-11\">",
"     3,8-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute, fulminant infections are usually due to Aspergillus species and the Mucorales.",
"     </li>",
"     <li>",
"      Indolent, chronic rhinosinusitis is most commonly caused by dematiaceous molds such as Bipolaris, Curvularia, and Alternaria spp, as well as by Aspergillus spp and other hyaline molds, such as Pseudallescheria boydii (also known as Scedosporium apiospermum, the asexual form of P. boydii). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=see_link\">",
"       \"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=see_link\">",
"       \"Epidemiology and clinical manifestations of Scedosporium infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Candida species have been reported to cause invasive rhinosinusitis in a patient with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/12\">",
"     12",
"    </a>",
"    ], and in a patient following hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/9\">",
"     9",
"    </a>",
"    ], but generally do not cause rhinosinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute fungal sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute fungal rhinosinusitis usually present acutely with fever, facial pain, nasal congestion, and epistaxis, and can have changes in vision or mentation. Facial numbness and diplopia can occur in the setting of cranial nerve involvement. Many patients already have extension of the infection outside the sinuses at the time of presentation.",
"   </p>",
"   <p>",
"    A high degree of suspicion must be maintained in the immunocompromised patient with sinus complaints, especially facial pain. The nares and oral cavity should be carefully examined for necrotic areas; early nasal endoscopic evaluation by an otolaryngologist is essential [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/13\">",
"     13",
"    </a>",
"    ]. Necrosis results from vascular invasion by the fungi and can appear as palatal or gingival eschars, or sloughing of the nasal septum with perforation. Sensation is frequently lost in the malar areas, and visual loss can occur with involvement of the orbit or optic nerve. Orbital involvement can also result in proptosis and fixation of the globe.",
"   </p>",
"   <p>",
"    Computed tomography (CT) shows sinus involvement, and may reveal bony erosions or extension of the infection to the globe, brain, cavernous sinus, or carotid artery (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66095 \" href=\"UTD.htm?29/0/29711\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. However, none of the findings on CT imaging are sufficiently specific to allow for a diagnosis of fungal versus bacterial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/16\">",
"     16",
"    </a>",
"    ]. Magnetic resonance imaging should be performed to assess intracranial and cavernous sinus involvement. The majority of patients with acute fungal rhinosinusitis have multiple sinuses involved, with the maxillary and ethmoid sinuses being the most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chronic fungal sinusitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the chronic, indolent form of invasive fungal rhinosinusitis usually present with symptoms of chronic rhinosinusitis and few, if any, systemic complaints. These patients are often elderly and only mildly immunosuppressed. Diabetes mellitus and low-dose glucocorticoids are risk factors that are often noted. Patients often endure the symptoms of chronic rhinosinusitis for months before the development of a complication, such as visual changes from orbital invasion or neurologic complaints due to brain involvement. The physical examination may reveal tenderness over the maxillary sinuses and erythema overlying the malar areas. Proptosis and fixation of the globe are seen with orbital involvement.",
"   </p>",
"   <p>",
"    CT scan frequently shows involvement of a single paranasal sinus with a mass lesion and thickening of the mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Bony erosions are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of invasive fungal rhinosinusitis is dependent upon histopathologic demonstration of fungal invasion by biopsy of involved areas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/17\">",
"     17",
"    </a>",
"    ]. Imaging modalities, such as CT scanning, are suggestive but are not sufficiently sensitive or specific to confirm a diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66095 \" href=\"UTD.htm?29/0/29711\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/16\">",
"     16",
"    </a>",
"    ]. Evaluation of patients with suspected fungal rhinosinusitis should include early nasal endoscopy with biopsies of affected tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/13\">",
"     13",
"    </a>",
"    ]. Cultures of the biopsy specimen are usually positive. Isolation of the infecting fungus is necessary to guide therapy. It is important to distinguish the agents of mucormycosis from Aspergillus and dematiaceous molds because antifungal therapies are different.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive rhinosinusitis remains a very difficult infection to cure because most affected patients are immunosuppressed. The diagnosis should be considered early in susceptible patients since prompt treatment is essential for cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of invasive rhinosinusitis in the appropriate host should warrant empiric antifungal therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , or if mucormycosis is ruled out,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . Assessment of the extent of infection should be accomplished with computed tomography or magnetic resonance imaging.",
"   </p>",
"   <p>",
"    Surgical evaluation should be conducted urgently for both diagnostic biopsy and for debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Surgical intervention is difficult in some patients because of the extent of the infection or the severity of the underlying disease. Radical surgical debridement is required in most cases to achieve cure, and sometimes requires multiple surgeries.",
"   </p>",
"   <p>",
"    Another important factor in treatment is the restoration of immune function by withdrawal of immunosuppressive medications or remission of the underlying immunosuppressive illness.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or a lipid formulation of amphotericin B (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) has been used as initial therapy of invasive fungal rhinosinusitis, particularly if mucormycosis is likely because the agents of mucormycosis are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    . We prefer one of the lipid formulations of amphotericin B rather than conventional amphotericin B deoxycholate in order to reduce nephrotoxicity. Exceptions to these general recommendations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection due to Pseudallescheria boydii (Scedosporium apiospermum) &mdash; P. boydii is generally resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=see_link\">",
"       \"Diagnosis and treatment of Scedosporium infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection due to Aspergillus species &mdash; The drug of choice for treatment of invasive infection due to Aspergillus species is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      at the dosages noted below. Alternatives for patients who are refractory to or intolerant of voriconazole are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or an echinocandin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8775/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections due to most dematiaceous fungi (phaeohyphomycosis) are likely to respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=see_link\">",
"       \"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The usual dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours for two doses, then 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every 12 hours. The IV formulation is recommended for at least the initial few days. Oral step-down therapy, using 200 mg twice daily, can be used following an initial response to the IV formulation. For serious infections, we recommend measurement of trough voriconazole levels in order to keep the trough serum concentration above 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and less than 5",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"     \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients initially receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    , the duration of intravenous therapy depends upon the underlying immune status of the host, the extent of surgical debridement, and the response to therapy. We recommend continuing intravenous therapy until there is a clear clinical response and reversal of as many of the immunocompromising conditions as possible (eg, recovery from neutropenia, tapering of glucocorticoids, or engraftment in stem cell transplant recipients). This usually requires weeks of therapy, and may require two to three months of therapy in patients with severe immunosuppression and slow clinical responses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;After improvement is noted, therapy can be changed to an oral antifungal agent. For patients with mucormycosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , at a dosage of 400 mg twice daily given with fatty foods, can be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link\">",
"     \"Pharmacology of azoles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic invasive fungal rhinosinusitis due to dematiaceous molds can be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    . Aspergillus, Scedosporium, and Fusarium spp infections should be treated with voriconazole. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=see_link\">",
"     \"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"     \"Treatment and prevention of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=see_link\">",
"     \"Diagnosis and treatment of Scedosporium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is to be used for suppressive therapy of chronic infections, we recommend using the oral solution and monitoring serum levels to make certain the drugs are at a therapeutic level. The liquid formulation of itraconazole overcomes problems caused by poor absorption of the capsule and achieves approximately 30 percent higher concentrations in the serum at the same dose. The solution should be given on an empty stomach to achieve the highest serum concentrations. However, more gastrointestinal upset occurs with the solution formulation, which precludes its use in some patients.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    has excellent absorption, patients receiving this agent should also undergo serum concentration monitoring since there is individual variation in its metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H28#H28\">",
"     \"Pharmacology of azoles\", section on 'Voriconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Suppressive therapy is usually continued for at least three to six months. Some patients who remain immunosuppressed require lifelong therapy.",
"   </p>",
"   <p>",
"    Patients whose rhinosinusitis has resolved, but who require further immunosuppressive therapy or who will receive a hematopoietic stem cell transplant, should be placed on an appropriate antifungal agent throughout the period of immunosuppression because of the high risk of relapse of invasive fungal rhinosinusitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49970672\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungal rhinosinusitis encompasses a wide variety of fungal infections that range from merely irritating to rapidly fatal. Fungal colonization of the upper and lower airways is a common condition, since fungal spores are constantly inhaled into the sinuses and lungs. However, colonization is distinct from infection, and most colonized patients do not become ill with fungal infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Fungal colonization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49971449\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The marked rise in the number of immunocompromised patients has led to an increase in unusual manifestations of aggressive fungal infections. Invasive rhinosinusitis is one such form of infection that appears to be increasing in frequency. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Invasive fungal sinusitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of immunosuppression in patients with invasive fungal rhinosinusitis are hematologic malignancies, hematopoietic stem cell transplantation, chemotherapy-induced neutropenia, solid organ transplantation, advanced HIV infection, diabetes mellitus, and glucocorticoid therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Invasive fungal sinusitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fungi most often implicated in causing invasive rhinosinusitis are species of Aspergillus, Fusarium, the Mucorales, and dematiaceous (brown-black) molds. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Invasive fungal sinusitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4524540\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with acute fungal rhinosinusitis usually present acutely with fever, facial pain, nasal congestion, and epistaxis, and can have changes in vision and mentation. Facial numbness or diplopia can occur in the setting of cranial nerve involvement. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute fungal sinusitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A high degree of suspicion must be maintained in the immunocompromised patient with sinus complaints, especially facial pain. The nares and oral cavity should be carefully examined for necrotic areas. Early nasal endoscopic evaluation by an otolaryngologist is essential. Necrosis results from vascular invasion by the fungi and can appear as palatal or gingival eschars, or sloughing of the nasal septum with perforation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Acute fungal sinusitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49971489\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of invasive fungal rhinosinusitis is dependent upon histopathologic demonstration of fungal invasion by biopsy of involved areas. Evaluation of patients with suspected fungal rhinosinusitis should include early nasal endoscopy with biopsies of affected tissues. Cultures of the biopsy specimen are usually positive. Isolation of the infecting fungus is necessary to guide therapy. It is important to distinguish the agents of mucormycosis from Aspergillus and dematiaceous molds because antifungal therapies are different. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49971497\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs and symptoms of invasive rhinosinusitis in the appropriate host should warrant empiric antifungal therapy with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , or if mucormycosis is ruled out,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical evaluation should be conducted urgently for both diagnostic biopsy and for debridement. Radical surgical debridement is required in most cases to achieve cure and sometimes requires multiple surgeries. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another important factor in treatment is the restoration of immune function by withdrawal of immunosuppressive medications or remission of the underlying immunosuppressive illness. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We prefer one of the lipid formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      dosed at 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV per day for the initial therapy of invasive fungal rhinosinusitis, particularly if mucormycosis is likely, because the agents of mucormycosis are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . Exceptions to this general recommendation include the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infection due to Pseudallescheria boydii (Scedosporium apiospermum) &mdash; P. boydii is generally resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      and should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=see_link\">",
"       \"Diagnosis and treatment of Scedosporium infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection due to Aspergillus species &mdash; The drug of choice for treatment of invasive infection due to Aspergillus species is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      at the dosages noted below. Alternatives for patients who are refractory to or intolerant of voriconazole are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      or an echinocandin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections due to most dematiaceous fungi (phaeohyphomycosis) are likely to respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=see_link\">",
"       \"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The usual dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      is 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours. The IV formulation is recommended for at least the initial few days. Oral step-down therapy, using 200 mg twice daily, can be used following an initial response to the IV formulation. It is essential to obtain voriconazole trough serum levels to ensure adequate concentrations and to avoid toxicity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients initially receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      , the duration of intravenous therapy depends upon the underlying immune status of the host, the extent of surgical debridement, and the response to therapy. We recommend continuing intravenous therapy until there is a clear clinical response and reversal of as many of the immunocompromising conditions as possible (eg, recovery from neutropenia, tapering of glucocorticoids, or engraftment in stem cell transplant recipients). This usually requires weeks of therapy, and may require two to three months of therapy in patients with severe immunosuppression and slow clinical responses. After improvement is noted, therapy can be changed to an oral antifungal agent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initial therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Suppressive therapy is usually continued for at least three to six months. Some patients who remain immunosuppressed require lifelong therapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/1\">",
"      Chakrabarti A, Denning DW, Ferguson BJ, et al. Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope 2009; 119:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/2\">",
"      Nicolai P, Lombardi D, Tomenzoli D, et al. Fungus ball of the paranasal sinuses: experience in 160 patients treated with endoscopic surgery. Laryngoscope 2009; 119:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/3\">",
"      Waitzman AA, Birt BD. Fungal sinusitis. J Otolaryngol 1994; 23:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/4\">",
"      Grosjean P, Weber R. Fungus balls of the paranasal sinuses: a review. Eur Arch Otorhinolaryngol 2007; 264:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/5\">",
"      Lee KC. Clinical features of the paranasal sinus fungus ball. J Otolaryngol 2007; 36:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/6\">",
"      Dufour X, Kauffmann-Lacroix C, Ferrie JC, et al. Paranasal sinus fungus ball and surgery: a review of 175 cases. Rhinology 2005; 43:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/7\">",
"      Pagella F, Matti E, De Bernardi F, et al. Paranasal sinus fungus ball: diagnosis and management. Mycoses 2007; 50:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/8\">",
"      deShazo RD, Chapin K, Swain RE. Fungal sinusitis. N Engl J Med 1997; 337:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/9\">",
"      Drakos PE, Nagler A, Or R, et al. Invasive fungal sinusitis in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/10\">",
"      Meyer RD, Gaultier CR, Yamashita JT, et al. Fungal sinusitis in patients with AIDS: report of 4 cases and review of the literature. Medicine (Baltimore) 1994; 73:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/11\">",
"      Mylonakis E, Rich J, Skolnik PR, et al. Invasive Aspergillus sinusitis in patients with human immunodeficiency virus infection. Report of 2 cases and review. Medicine (Baltimore) 1997; 76:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/12\">",
"      Colmenero C, Mo&ntilde;ux A, Valencia E, Castro A. Successfully treated candida sinusitis in an AIDS patient. J Craniomaxillofac Surg 1990; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/13\">",
"      DelGaudio JM, Clemson LA. An early detection protocol for invasive fungal sinusitis in neutropenic patients successfully reduces extent of disease at presentation and long term morbidity. Laryngoscope 2009; 119:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/14\">",
"      Heier JS, Gardner TA, Hawes MJ, et al. Proptosis as the initial presentation of fungal sinusitis in immunocompetent patients. Ophthalmology 1995; 102:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/15\">",
"      Roithmann R, Shankar L, Hawke M, et al. Diagnostic imaging of fungal sinusitis: eleven new cases and literature review. Rhinology 1995; 33:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/16\">",
"      DelGaudio JM, Swain RE Jr, Kingdom TT, et al. Computed tomographic findings in patients with invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg 2003; 129:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/17\">",
"      Ghadiali MT, Deckard NA, Farooq U, et al. Frozen-section biopsy analysis for acute invasive fungal rhinosinusitis. Otolaryngol Head Neck Surg 2007; 136:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/18\">",
"      Gillespie MB, O'Malley BW. An algorithmic approach to the diagnosis and management of invasive fungal rhinosinusitis in the immunocompromised patient. Otolaryngol Clin North Am 2000; 33:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/19\">",
"      S&uuml;sl&uuml; AE, O��retmeno��lu O, S&uuml;sl&uuml; N, et al. Acute invasive fungal rhinosinusitis: our experience with 19 patients. Eur Arch Otorhinolaryngol 2009; 266:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/20\">",
"      Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8775/abstract/21\">",
"      Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:327.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2452 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8775=[""].join("\n");
var outline_f8_36_8775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49970672\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNGAL COLONIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fungus balls",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INVASIVE FUNGAL SINUSITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute fungal sinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chronic fungal sinusitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49970672\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49971449\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4524540\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49971489\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49971497\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2452\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2452|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/0/29711\" title=\"diagnostic image 1\">",
"      Aspergillus sinusitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43894?source=related_link\">",
"      Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/25/36249?source=related_link\">",
"      Diagnosis and treatment of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=related_link\">",
"      Epidemiology and clinical manifestations of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_36_8776="Rape";
var content_f8_36_8776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50009%7EEM%2F62823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50009%7EEM%2F62823&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Traumatic rape of child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Injury unable to be assessed without sedation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc R. Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Traumatic rape of child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note 3rd degree laceration which was repaired in layers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc R.&nbsp;Laufer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8776=[""].join("\n");
var outline_f8_36_8776=null;
var title_f8_36_8777="Personalized medicine";
var content_f8_36_8777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Personalized medicine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8777/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8777/contributors\">",
"     Anne Slavotinek, MBBS, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8777/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/36/8777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2097359\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the rapid pace of progress in the fields of biotechnology, genetics, and genomics, molecular genetic profiling may soon become an integral tool for clinicians to guide individualized management of many medical conditions. Personalized medicine (also termed personalized genomics, genomic medicine, or precision medicine) refers to the application of patient-specific profiles, incorporating genetic and genomic data as well as clinical and environmental factors, to assess individual risks and tailor prevention and disease management strategies.",
"   </p>",
"   <p>",
"    Advocates for personalized medicine cite its potential to yield significant health and economic benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improved medical decision making",
"     </li>",
"     <li>",
"      Delivery of appropriate therapies",
"     </li>",
"     <li>",
"      Optimized disease prevention strategies",
"     </li>",
"     <li>",
"      Reduced incidence of treatment-related complications",
"     </li>",
"     <li>",
"      Reduced healthcare costs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skeptics argue that, while there are selected examples where specific biomarkers or genetic tests can help guide medical decision making, more wide-scale profiling remains largely unrealistic. Factors cited to support this viewpoint include the high costs of testing, the lack of reliable predictive biomarkers for most conditions, the lack of clear therapeutic alternatives (based on genetic differences) for many conditions, and the lack of knowledge and expertise among most clinicians regarding genetics, risk prediction, and genetic counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonetheless, momentum for the implementation of personalized medicine in clinical practice is gaining. The price of exome sequencing and whole genome sequencing is dropping quickly, and the catalog of disease-associated genetic variations, produced from genome-wide association studies, array comparative genomic hybridization (array CGH), and next-generation sequencing (including exome sequencing and whole genome sequencing), is rapidly increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/3\">",
"     3",
"    </a>",
"    ]. A 2012 literature search of the term &ldquo;personalized medicine&rdquo; yields more than 9000 papers, and journals dedicated to the subject have been launched. Despite obstacles, there is strong support for the development of personal genomics among healthcare policy makers and research funding agencies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the current state of personalized medicine, including a review of direct-to-consumer genetic testing services, and the challenges and obstacles confronted in the broad implementation of genomics in the clinic. The principles and techniques that underlie these tests, and counseling for genetic testing, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39799?source=see_link\">",
"     \"Tools for genetics and genomics: Gene expression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link\">",
"     \"Overview of pharmacogenomics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/44/10950?source=see_link\">",
"     \"Principles of complex trait genetics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For discussions of specific tests, readers are referred to disease-specific topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097366\">",
"    <span class=\"h1\">",
"     THE PERSONALIZED HEALTH CARE INITIATIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In March 2007, the Department of Health and Human Services in the United States launched the Personalized Health Care Initiative (PHCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/5\">",
"     5",
"    </a>",
"    ]. This initiative proposed a set of goals &ldquo;for achieving gene-based medical care combined with health information technology.&rdquo; PHCI aims to accelerate the development of personalized treatment strategies and transform the practice of medicine towards individualized patient care.",
"   </p>",
"   <p>",
"    Components of the program include translational research initiatives to develop high throughput sequencing technologies (ie, next-generation sequencing), enhanced mapping of the genetic determinants of disease and drug responsiveness, development of an informatics infrastructure to promote electronic medical records, and broad implementation of genomic data. &nbsp;",
"   </p>",
"   <p>",
"    Advocates of such a system argue that personalized medicine would have numerous tangible benefits for patients, practitioners and society, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Customized treatment plans that consider the unique biological processes of the disease and the patient&rsquo;s drug response profiles.",
"     </li>",
"     <li>",
"      Reduced exposure to medications of lower efficacy or greater toxicity, thereby reducing the incidence of serious side effects and improving patient tolerance and compliance.",
"     </li>",
"     <li>",
"      Overall reduced healthcare costs by expeditious delivery of optimal treatments, avoidance of toxic medications, reduced complication rates, and avoidance of more costly medications when less expensive alternatives of similar (or greater) efficacy are available.",
"     </li>",
"     <li>",
"      More specific, targeted recommendations for lifestyle and behavioral modification or other disease prevention strategies.",
"     </li>",
"     <li>",
"      Enhanced patient satisfaction with the treatment process and medical team.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Currently available biomarker assays are already impacting the practice of several medical specialties, most notably in hematology and oncology. The availability of genomic sequence data related to all genes is anticipated to have the greatest impact on primary care, particularly with regard to disease prevention. Genomic profiles could allow primary care physicians to focus on lifestyle modifications and disease prophylaxis strategies that are tailored to individual risk, maximizing effective use of their contact time with patients to focus on the most pertinent risks and intervention strategies.",
"   </p>",
"   <p>",
"    Several studies have demonstrated that the availability of genetic information enhances patient compliance with behavior modification and other disease prevention strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/6-10\">",
"     6-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 199 smokers, individuals who were homozygous for a severely deficient, alpha-1-antitrypsin null allele were significantly more likely to attempt to quit smoking (59 percent) than either mutation carriers (34 percent) or individuals with a normal genotype (26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 261 smokers who were asked to consider one of two randomly assigned hypothetical scenarios, subjects who were informed of having genetic risk factors for heart disease were more likely to report an inclination to quit smoking than individuals in a high-risk (but non-genetic) group [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/9\">",
"       9",
"      </a>",
"      ]. A substantial proportion of respondents reported that their decisions were motivated by the belief that smoking cessation would translate to reductions in heart disease, suggesting that genetic determinism would not negatively influence the ability to modify behavior and improve risk factor avoidance.",
"     </li>",
"     <li>",
"      In a study of 781 individuals who were carriers of mutations that cause familial hypercholesterolemia (ascertained through an affected relative), cholesterol-lowering medication use increased from 51 to 81 percent two years after learning genotype status [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/10\">",
"       10",
"      </a>",
"      ]. Significant reductions in low-density lipoprotein C levels were noted, although normalized levels were not achieved in most subjects.",
"     </li>",
"     <li>",
"      What is not clear is whether genetic information for individuals who have no &ldquo;a priori&rdquo; increased risk prior to genetic testing will lead to change in lifestyle behaviors. In a sample of over 2000 patients who completed genomewide testing through a direct-to-consumer vendor (Navigenics), testing did not result in any short-term change in diet or exercise behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097373\">",
"    <span class=\"h1\">",
"     PERSONALIZED MEDICINE TODAY: GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general terms, clinical genetics has focused on three types of genetic variation: (i) relatively rare, disease-causing mutations that are associated with Mendelian diseases; (ii) more common variants that are associated with an increased risk of complex diseases; (iii) and sequence variants that modulate drug response (pharmacogenetic variants). Broadly, three types of genetic tests are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific single gene tests &mdash; Most gene-specific tests are performed as part of a focused risk evaluation for heritable disease or for diagnostic considerations. Examples include",
"      <em>",
"       BRCA1",
"      </em>",
"      and",
"      <em>",
"       BRCA2",
"      </em>",
"      gene sequencing for carrier identification in at risk individuals with a strong family history of breast cancer and",
"      <em>",
"       VKORC1",
"      </em>",
"      genotyping for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      pharmacogenetic testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"       \"Genetic counseling and testing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link\">",
"       \"Overview of pharmacogenomics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genotyping panels of selected susceptibility variants &mdash; These panels are usually bundled as direct-to-consumer (DTC) genetic tests and include single nucleotide polymorphisms (SNPs) that have been associated with common, non-Mendelian or complex traits such as type 2 diabetes, autoimmune disease, and metabolic traits. Due to the inherent genetic complexities of these disorders, the genetic effects conferred by each of the SNPs are often relatively weak (odds ratios of &lt;1.5 for risk variants) and inconsistent across different ethnic populations. The predictive accuracy of these tests therefore is highly variable and most such panels have not been comprehensively validated. (See",
"      <a class=\"local\" href=\"#H2097388\">",
"       'Direct-to-consumer testing'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Next-generation sequencing &mdash; New high-throughput sequencing platforms (exome sequencing or whole genome sequencing) now enable sequencing of the coding regions of the human genome (exome sequencing) or near complete whole genome sequencing in a matter of days. Though currently unaffordable to many, the price of next-generation sequencing continues to fall. Exome sequencing can now be performed for less than $1000 as a research test, although the costs of exome sequencing as a clinical test or whole genome sequencing are substantially higher. A list of laboratories currently offering clinical exome sequencing is available through the",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/clinical_lab_service_id/308026?db=genetests\">",
"       National Center for Biotechnology Information",
"      </a>",
"      website. The genomic results are comprehensive and highly accurate depending on the depth of sequencing coverage, but a substantial proportion of the identified variants will be rare, often &ldquo;private&rdquo; to the individual or family, and the clinical and prognostic consequences of many of these sequence variants are unknown. However, there are several large, publically-accessible databases that contain data from genotyping and sequencing studies that can be used to search for the frequency of a given sequence variant in the general population (eg, the",
"      <a class=\"external\" href=\"file://evs.gs.washington.edu/EVS/\">",
"       Exome Variant Server from the National Heart Lung Blood Institute Exome Sequencing Project",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2097381\">",
"       'Next-generation sequencing (exome sequencing and whole genome sequencing)'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H582867830\">",
"    <span class=\"h2\">",
"     Genotyping panels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotyping refers to testing for the allelic status of an individual at known polymorphic loci. In contrast to sequencing, genotype assays are designed from previous knowledge of the existence of a particular genetic variant, commonly a single nucleotide polymorphism (SNP). Numerous CLIA-certified genotyping technologies have been developed for simultaneous characterization of dozens to hundreds of loci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=see_link\">",
"     \"Genetic counseling and testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, publication of more than 500 genome-wide association studies (also referred to as GWAS) have identified thousands of common variants that confer only a small to modest risk for more than 200 common conditions. These findings have led to the development of genotyping panels for testing for many of these variants. Several commercial companies use a variety of such panels to offer genotyping services to the public (",
"    <a class=\"graphic graphic_table graphicRef60842 \" href=\"UTD.htm?29/13/29917\">",
"     table 1",
"    </a>",
"    ). The SNP content and diseases covered vary from panel to panel, although there is overlap among the most commonly studied variants. The predictive accuracy of these panels is highly variable, and the clinical utility of these tests has not been established and remains unclear at present. (See",
"    <a class=\"local\" href=\"#H2097388\">",
"     'Direct-to-consumer testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097456\">",
"    <span class=\"h2\">",
"     Pharmacogenetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest clinical implementations of genetic profiling have been in the area of pharmacogenetics, also referred to as pharmacogenomics. Pharmacogenetics is the study of variability in drug response due to genetic factors, and includes the prediction of a patient&rsquo;s response to a specific therapy and susceptibility to adverse events. Pharmacogenetic data may inform both the selection of a particular treatment and the individualized dosing schedule for that treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link\">",
"     \"Overview of pharmacogenomics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug labels for numerous drugs include information regarding available pharmacogenetic biomarkers. Though most notably impacting hematology and oncology, pharmacogenetic markers are also available for medications used in the treatment of infectious diseases as well as cardiac, rheumatologic, and pulmonary diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/12\">",
"     12",
"    </a>",
"    ]. Label content includes warnings regarding genotype-specific contraindications or toxicities, dosing recommendations, or information regarding the availability of genetic tests (without specific recommendations for testing). An updated listing of pharmacogenetic biomarkers cited in drug labels in the United States is available on the",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm\">",
"     US Food and Drug Administration",
"    </a>",
"    website.",
"   </p>",
"   <p>",
"    The most extensively studied pharmacogenetic variants are those of the cytochrome P450 drug metabolizing liver enzymes (CYPs). Fifty-eight CYPs have been characterized in humans, and functional genetic polymorphisms that alter functional activity have been identified for many CYPs. The Amplichip&reg;",
"    <em>",
"     CYP450",
"    </em>",
"    test is clinically available in the United States as a DNA oligonucleotide genotyping microarray for simultaneous characterization of 29 single nucleotide polymorphisms (SNPs) in the genes",
"    <em>",
"     CYP2D6",
"    </em>",
"    and",
"    <em>",
"     CYP2C19",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/13\">",
"     13",
"    </a>",
"    ]. These variants influence the metabolism of a wide range of commonly prescribed medications, including 33 with pharmacogenetic biomarker labels. However, this test has not been widely adopted for clinical use, since the clinical value of this array has not been validated in prospective studies and insurance reimbursement is not available at present.",
"   </p>",
"   <p>",
"    A number of studies have demonstrated the predictive utility of pharmacogenetic testing in determining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dosing. Pharmacogenetic testing of",
"    <em>",
"     CYP2C9",
"    </em>",
"    and vitamin K activating enzyme (",
"    <em>",
"     VKORC1",
"    </em>",
"    ), to tailor initiating dosing of warfarin, is being evaluated in multiple prospective clinical trials to confirm the clinical utility of such testing (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link&amp;anchor=H14#H14\">",
"     \"Therapeutic use of warfarin\", section on 'Pharmacokinetic and pharmacogenetic dosing'",
"    </a>",
"    ). In a randomized trial of clinical effectiveness comparing pharmacogenetic algorithms based on",
"    <em>",
"     CYP2C9",
"    </em>",
"    and",
"    <em>",
"     VCORC1",
"    </em>",
"    genotyping, compared to controls, for individuals where pharmacogenetic guidance was utilized for dosing, warfarin use was associated with fewer out-of-range international normalized ratios (INRs) and fewer serious adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097381\">",
"    <span class=\"h2\">",
"     Next-generation sequencing (exome sequencing and whole genome sequencing)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three major criticisms of personal genomics are the lack of a complete catalog of relevant genetic variation, methodological limitations to comprehensively and reliably assay variation at low cost, and lack of evidence that patient outcomes are improved.",
"   </p>",
"   <p>",
"    Though SNP-specific genotyping panels produce accurate data, these assays typically interrogate a small fraction (&lt;200 variants) of the human genome sequence. In contrast, whole genome sequencing can theoretically provide information regarding all SNPs and genetic variants, including alterations in copy number. As more knowledge is gained regarding the spectrum of disease-causing variation and catalogs of such variation are assembled, complete sequence information is expected to provide greater predictive accuracy over genotyping panels. As a consequence, a fierce competition is ongoing to develop technologies for affordable complete genome sequencing.",
"   </p>",
"   <p>",
"    As of 2011, at least five platforms are available for whole genome sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/15\">",
"     15",
"    </a>",
"    ]. It is anticipated that whole genome sequencing for under $1000 will be realized in the near future. At such prices, the affordability of obtaining complete sequence data will become a moot issue, given that the information generated will be of use for the patient&rsquo;s lifetime and will be relevant across all medical fields. In addition, for genetically-heterogeneous disorders, such prices will be less than the costs of Sanger sequencing that is currently performed for multiple genes. On a per locus basis (if each relevant genotype were to be considered as a separate test) these tests are also less expensive than virtually all diagnostic tests currently performed (including basic chemistries and blood counts). At present, genome-wide sequencing costs can be reduced by focusing on the coding portion of the genome&mdash;exons. So-called &ldquo;exome sequencing,&rdquo; in which only the ~3 percent of DNA that is transcribed to messenger RNA is sequenced, can be achieved at a lower price than whole genome sequencing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/15\">",
"     15",
"    </a>",
"    ]. Although this approach will characterize many of the potentially-deleterious mutations that alter protein structure or abundance, exome sequencing is unable to characterize the noncoding, regulatory variants that are thought to contribute to complex traits and is less good at detecting copy number variants. Exome sequencing was marketed direct-to-consumers at $999 in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/16\">",
"     16",
"    </a>",
"    ]. As the price of whole genome sequencing falls, the utility of exome sequencing may decrease. &nbsp;",
"   </p>",
"   <p>",
"    As the price of genome sequencing falls to levels comparable with genome-wide genotyping arrays, susceptibility and pharmacogenetic mapping studies will enable more complete characterization of the genetic basis of disease and pharmacologic response. Genome sequencing will capture both common and rare SNPs and can detect copy number variants, thereby substantially improving the predictive utility of genetic tests. However, optimal detection of copy number variants still requires array comparative genomic hybridization (CGH).",
"   </p>",
"   <p>",
"    Although the technical challenges posed by whole genome sequencing are quickly being overcome, additional concerns remain to be addressed. The most pressing is the lack of prognostic or functional understanding for most of the variants that are being identified. From available whole genome sequence data in 2010, an average sequence identified between 3.0 and 3.6 million variants, with approximately 15 to 20 percent of the identified variants (0.5 to 0.75 million SNPs) being novel and not reported in public genetic databases such as dbSNP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/17\">",
"     17",
"    </a>",
"    ]. For a sequenced exome, approximately 20,000 to 24,000 sequence variants are obtained per individual [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/18\">",
"     18",
"    </a>",
"    ]. Until the relevance of these variants in health and disease is understood, interpretation of genomic sequence data will be significantly limited. As described above, however, public databases for variant interpretation exist and are improving.",
"   </p>",
"   <p>",
"    Two reports of whole genome sequencing highlight this challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/17,19\">",
"     17,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A whole genome sequence analysis of an otherwise healthy individual with Charcot-Marie-Tooth (CMT) disease, in addition to facilitating the identification of the CMT-causing mutations, identified a total of 159 mutations with known disease (or trait) associations, including 33 variants associated with cancers, 48 associated with complex diseases, and 21 associated with Mendelian (monogenic) diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/17\">",
"       17",
"      </a>",
"      ]. In the absence of significant family history for most of these conditions, it is unclear how to interpret or manage these variants. However, longitudinal follow-up of the patient may be helpful as new data become available.",
"     </li>",
"     <li>",
"      A whole genome sequence analysis in a healthy 40-year-old man with a family history of coronary artery disease, and sudden death in one of 27 relatives, identified numerous variants associated with both rare and common conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/19\">",
"       19",
"      </a>",
"      ]. Variants included three mutations previously associated with sudden cardiac death. Predictive models were applied for 32 conditions, with posterior probability estimates suggesting substantially increased risk for the development of obesity, myocardial infarction (from 2 percent pre-testing to 8.9 percent post-testing), type II diabetes (27 to 54 percent), prostate cancer (16 to 23 percent) and depression, and a reduced risk for Alzheimer&rsquo;s disease (9 to 1.37 percent). Based upon these results, in conjunction with the patient&rsquo;s strong family history of atherosclerosis, the patient&rsquo;s physician advised initiating lipid-lowering therapies despite the patient having a blood lipid profile for which treatment would not otherwise be recommended by current guidelines. Given the anecdotal nature of this report and the lack of prospective data, it is unclear whether any gains were achieved from the availability of the sequence data.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two additional reports, however, indicate the potential for whole genome sequencing to yield clinically meaningful information that would not be accessible through classic cytogenetic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whole genome sequencing was performed on skin and leukemic cells from a patient with a history of early breast cancer and ovarian cancer, who subsequently developed acute myeloid leukemia and was negative for",
"      <em>",
"       BRCA1",
"      </em>",
"      and",
"      <em>",
"       BRCA2",
"      </em>",
"      gene mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/20\">",
"       20",
"      </a>",
"      ]. The patient had a heterozygous deletion of exons in the",
"      <em>",
"       TP53",
"      </em>",
"      gene in the skin cells, with loss of the intact copy in the leukemic cells due to uniparental disomy. Identification of the",
"      <em>",
"       TP53",
"      </em>",
"      mutation resulting in Li-Fraumeni syndrome allowed her children to undergo early surveillance for cancers and consider preventive surgical options.",
"     </li>",
"     <li>",
"      Whole genome sequencing was performed in a patient with acute myelogenous leukemia whose clinical presentation suggested acute promyelocytic leukemia but whose cytogenetic studies indicated a less favorable subtype that would require bone marrow transplantation during first remission [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/21\">",
"       21",
"      </a>",
"      ]. Sequencing identified a fusion gene with a translocation on chromosome 17, leading to a treatment option with retinoic acid in lieu of marrow transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13119540\">",
"    <span class=\"h2\">",
"     Fetal personalized medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the recognition that a sufficient quantity of fetal DNA is present in the maternal circulation for clinical study, and with improvements in both amniocentesis and chorionic villus sampling, it is becoming increasingly easier and safer to accurately assess the structural integrity and sequence variation of fetal genomes. Consequently, prenatal genetic testing is playing an ever-increasing role in obstetrical care, with a move towards implementation of personalized approaches in fetal medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example is the implementation of a noninvasive perinatal test (NIPT) of cell-free fetal DNA (ffDNA) sequences from maternal blood samples for the Rhesus D blood group (RhD) allele. In about 10 percent of non-Hispanic white pregnancies, seronegative RhD mothers carry an RhD-positive fetus. These mothers are at risk of RhD sensitization during delivery, with consequential risk to subsequent RhD-positive pregnancies for life-threatening hemolytic crises. Maternal sensitization is preventable with timely administration of anti-D antibodies, and second-trimester anti-D prophylaxis of RhD-negative mothers is now a standard of prenatal care. However, about 40 percent of RhD-negative mothers (those carrying RhD-negative fetuses) receive anti-RhD (a blood product) unnecessarily. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=see_link\">",
"     \"Management of pregnancy complicated by Rhesus (Rh) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noninvasive genotyping assays have been developed that type the RHD allele in cell-free fetal DNA (ffDNA) circulating in maternal plasma. The assay has a diagnostic accuracy approaching 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/23\">",
"     23",
"    </a>",
"    ], with better accuracies noted with newer assays that include rigorous positive controls that confirm sufficient quantities of circulating fetal DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the test performs less well in non-white populations, due to the presence of additional sequence variants. Noninvasive screening of RhD-negative pregnancies using this method could spare about 40 percent from unnecessary exposure to anti-RhD therapy and avoid more invasive testing (ie, amniocentesis) in previously sensitized mothers during subsequent pregnancies. Many European countries of predominantly white ancestry have implemented routine ffDNA screening for RhD-sensitized mothers. Fewer support the more generalized screening in all RhD-negative mothers, largely due to the current high costs of mass screening. For example, a recent cost-effectiveness analysis in the United Kingdom concluded that at current test and immunization costs, routine ffDNA screening of all RhD-negative mothers would not result in cost-savings or appreciable health benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/25\">",
"     25",
"    </a>",
"    ]. However, strategies to lower the costs of testing, including bundling of this test with others (such as for other blood groups, structural genetic aberrations, etc.), may eventually motivate its implementation more broadly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097388\">",
"    <span class=\"h2\">",
"     Direct-to-consumer testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing for disease susceptibility variants is now accessible to the general public through direct-to-consumer (DTC) testing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/26\">",
"     26",
"    </a>",
"    ]. The services can be purchased by phone or over the internet. A saliva collection kit is mailed to the customer, who subsequently returns the collected sample to the company for DNA extraction and testing. The advantages of such services include greater patient autonomy in choosing to undergo genetic testing.",
"   </p>",
"   <p>",
"    Reports of results are typically emailed directly to the patients or their physicians or can be made available online via a password-protected interface. The contents of the reports vary according to the company, but typically include specific genotype results, presented together with genotype-specific risk estimates, risks for specific diseases, or drug metabolism profiles. After genotyping, the SNP results are compared in affected and unaffected individuals and populations. Alleles that are more common in affected populations and exhibit odds ratios &gt;1 are considered to be risk alleles. Alleles can also occur less frequently in patients and have odds ratios &lt;1; these alleles may protect against the development of a disease. It is important to recognize that an estimate of disease-risk is not equivalent to the diagnosis of a disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many of the genotyping services are CLIA certified, such certification typically pertains only to the accuracy of the genotypes generated and not to the interpretation of their clinical significance. The accuracy of the absolute or relative risk estimates for individual conditions are dependent on the risk models (ie, literature-based risk estimates, combined with covariates such as age, gender, or other risk factors) used.",
"   </p>",
"   <p>",
"    Direct to consumer testing in 2011 almost exclusively entails testing based upon genotyping panels (",
"    <a class=\"graphic graphic_table graphicRef60842 \" href=\"UTD.htm?29/13/29917\">",
"     table 1",
"    </a>",
"    ). While the pricing of whole genome sequencing currently precludes its use, genotype-based panels are affordable to larger segments of the population. As a consequence, practitioners are frequently confronted by patients with questions related to the utility of these tests, or to assist in their interpretation. Unfortunately, few references are available to aid clinicians, necessitating direct consultation of physicians with company representatives for assistance and a reliance on the company for interpretation of results. Though most of the companies advertise access to professional genetic counselors for assistance in results interpretation, these services are usually offered at an additional cost (frequently higher than the cost of the test itself).",
"   </p>",
"   <p>",
"    A review of the CLIA certified services that offer large-scale genotyping panels or next-generation sequencing is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef60842 \" href=\"UTD.htm?29/13/29917\">",
"     table 1",
"    </a>",
"    ). A list of available DTC companies and genetic tests (updated August 11, 2011) is available from the",
"    <a class=\"external\" href=\"file://www.dnapolicy.org/news.release.php?action=detail&amp;pressrelease_id=145\">",
"     Genetics and Public Policy Center",
"    </a>",
"    . HYPERLINK",
"   </p>",
"   <p>",
"    Given the heterogeneity among DTC vendors in the markers tested and the predictive models used to develop risk estimates, questions have been raised regarding the reliability and reproducibility of these services. Two studies have evaluated these issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study compared genotyping panels from two DTC companies: 23andMe and Navigenics [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/28\">",
"       28",
"      </a>",
"      ]. DNA from five subjects was sent to each company for testing. Genotype calls (ie, the genotypes reported at each locus) were in excellent agreement (&gt;99 percent concordance). In contrast, risk prediction for diseases (increased versus decreased) was concordant in all five subjects for a minority of conditions (4 of 13). Disagreement between predictions was noted more than 50 percent of the time for seven conditions. Conditions that demonstrated strong agreement were those where the same SNP was tested by both companies, and the genetic effect of the SNP tested is very high (for example, the SNP for celiac disease that confers a sevenfold increase in risk). SNPs with such strong effects are uncommonly observed in common complex diseases.",
"     </li>",
"     <li>",
"      A second study evaluated the concordance across three companies (23andMe, Navigenics and deCODE), although only one sample was tested [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/29\">",
"       29",
"      </a>",
"      ]. Findings were similar to the earlier study: genotype concordance was high (99.6 percent; ie, analytical validity of the available tests was high [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/27\">",
"       27",
"      </a>",
"      ]) but significant variability in risk prediction was noted with undetermined clinical validity and utility. The variability in risk prediction was influenced by the SNPs that were genotyped for each condition and the reference population used [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/29\">",
"       29",
"      </a>",
"      ]. Diseases for which genotyped SNPs have strong predictive value were more likely to receive similar risk estimates from different DTC companies [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/27\">",
"       27",
"      </a>",
"      ]. This study also pointed out the need for risk data that is based upon client ethnicity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/29\">",
"       29",
"      </a>",
"      ], as the majority of genome-wide association studies have focused on Caucasians, with uncertain applications to other ethnicities, including Asian, African, and Hispanic [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Though more rigorous studies should be performed that include a larger panel of subjects of diverse demographic and disease risk, these early reports suggest that risk prediction remains unreliable at present, and interpretation of results for most SNPs should be approached with caution. In addition, patients should be made aware that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all but a limited number of SNPs of large risk, the majority of SNPs tested provide only incremental changes in a patient&rsquo;s risk profile.",
"     </li>",
"     <li>",
"      Prospective studies of the predictive accuracy of these products have not been performed, thus precluding the provision of effective counseling or reliable decision making for most results.",
"     </li>",
"     <li>",
"      There is substantial inter-company variability in the estimates reported [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/27,29\">",
"       27,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The influence of non-genetic factors, including race and lifestyle factors, on the interpretation of these results is unknown for many of the SNPs tested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The DTC genetic testing industry is rapidly evolving, and various legislative and regulatory bodies are actively developing policies regarding these services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097395\">",
"    <span class=\"h1\">",
"     OTHER PERSONALIZED MEDICINE PLATFORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early and intuitive focus for personalized medicine has been the development of genetic-based tests. Other &ldquo;omic&rdquo; approaches are being developed that will provide a more complete characterization of risk that includes variation between individuals in gene regulation, epigenetics, and cellular metabolism. Such approaches, currently in development and early adoption, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gene expression profiling (also referred to as transcriptomics) ��� Analysis of mRNA (of either individual genes or panels of gene targets), representing gene expression patterns; often uses microarray technology although whole transcriptome analysis is also possible. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39799?source=see_link\">",
"       \"Tools for genetics and genomics: Gene expression\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Proteomics ��� Qualitative and quantitative analysis of the collection of protein constituents in a biological sample. Typically performed using modification of polyacrylamide gel electrophoresis (PAGE) or matrix-assisted laser",
"      <span class=\"nowrap\">",
"       desorption/ionization",
"      </span>",
"      (MALDI) approaches, these methods provide measures of the types and abundance of proteins in a sample. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\", section on 'Proteomics'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metabolomics ��� The characterization of metabolic profiles; typically consists of a collection of assays that characterize panels of metabolites related to specific pathways. These studies can be static (cross-sectional profiling at a given timepoint) or dynamic (assessing the change in profile patterns following a specific metabolic challenge) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/30\">",
"       30",
"      </a>",
"      ]. In combination with separation methods such as high performance liquid chromatography or gas chromatography, metabolites are typically characterized either by mass spectrometry (MS) or nuclear magnetic resonance spectroscopy (NMR).",
"     </li>",
"     <li>",
"      Lipidomics ��� Characterization of the complete collection of lipids. Lipid structures, like metabolites, can be differentiated by MS or NMR [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. These methods are being applied towards the development of diagnostic tests that assess the lipid composition of cell membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few of these applications currently are being used routinely in clinical practice although development of reliable, clinically adaptable assays for these platforms is actively being pursued. One important exception is in the field of oncology, where gene expression profiling of malignant tissue is becoming an important diagnostic and prognostic tool. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Gene expression is dynamic and influenced by a range of cellular, genetic and environmental factors. These features make gene expression a particularly attractive target for profiling disease states, particularly malignant cell types. Some of the earliest and most successful implementations of gene expression profiling in oncology focused on single genes, such as determining estrogen receptor expression status in breast cancer for informing prognosis and chemotherapeutic options [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/34\">",
"     34",
"    </a>",
"    ]. More recently, whole transcriptome expression profiling technologies have been applied to tumor samples, with notable success [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2097402\">",
"    <span class=\"h1\">",
"     OBSTACLES FOR IMPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite early successes in the clinical introduction of a limited number of pharmacogenetic assays, multiple barriers preclude the widespread implementation of personalized medicine as standard clinical practice across all medical fields. The development of validated biomarkers and genetic assays represents an important bottleneck, although it is likely that the prospect of very affordable exome and whole genome sequencing will remove this obstacle in the near future. Other more formidable ethical and data storage challenges will remain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Limited predictive value of most tests &mdash;",
"      </strong>",
"      In 2012, there are few examples where genetic testing provides substantial gains in guiding therapeutic recommendations, although diagnostic genetic testing may be very useful for patient management and recurrence risk estimation. Although the number of genetic variants associated with disease susceptibility and pharmacogenetic response continues to increase, the current impetus to implement large-scale personalized genetics programs remains limited.",
"     </li>",
"     <li>",
"      <strong>",
"       Physician knowledge",
"      </strong>",
"      ��� The lack of general knowledge of genetics among most medical practitioners is perhaps the most pressing challenge preventing broad implementation of personalized medicine. Most medical practitioners do not feel adequately prepared to provide counseling for genetic testing [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/37\">",
"       37",
"      </a>",
"      ] but the number of genetic counselors and clinical geneticists in North America (approximately 2500 and 1100 respectively in 2010) has been hypothesized to be lower than could meet expected demands.",
"      <br/>",
"      <br/>",
"      In 2012, genetics has a limited role in clinical practice. Medical schools are actively developing curricula content in the areas of personalized medicine to prepare the next generation of physicians, including several programs that have developed case-studies of whole genome sequence data [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. However, there is little infrastructure in place to facilitate the education of clinicians already in practice.",
"      <br/>",
"      <br/>",
"      To bridge the knowledge gaps, reporting will be needed to be structured with clinical annotation to provide detailed interpretations, including detailed summaries of estimated disease risks, advisories based on the types of identified pharmacogenetic variants, and reports of identified novel variations of unclear clinical significance.",
"     </li>",
"     <li>",
"      <strong>",
"       Informatics infrastructure",
"      </strong>",
"      ��� In 2012, archiving of clinical laboratory data resides with the health care providers (and their affiliated institutions) who originally requested the tests. This model is inadequate to accommodate next-generation sequence data, and newer approaches that include an easily accessible electronic medical record (EMR) will be needed.",
"      <br/>",
"      <br/>",
"      In 2012, a minority of medical practices and hospitals in the United States have fully functioning EMR systems, and less than 50 percent have instituted any form of EMR [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. The majority of those in place would require substantial enhancement to accommodate the data storage and processing needs anticipated. The Personalized Health Care Initiative has made the nationwide development of EMRs a top priority [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/5\">",
"       5",
"      </a>",
"      ], and the Office of National Coordination for Health Information Technology (ONC) was established in 2004 by executive order to facilitate the establishment of an EHR across the United States. Significant stimulus funding was provided to catalyze the development of a national EMR by 2014.",
"     </li>",
"     <li>",
"      <strong>",
"       Information providence",
"      </strong>",
"      ��� Many questions arise when considering how personal genomic information should be managed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Who would be responsible for ordering a pharmacogenetic genotyping panel (ie, the major CYP loci) that profiles responsiveness for a wide array of drugs?",
"     </li>",
"     <li>",
"      How would such information be transmitted to other clinicians and pharmacists?",
"     </li>",
"     <li>",
"      When should genomic profiling be ordered? If personal genomic profiling is performed as part of a neonatal screening program, who will be the purveyors of such data?",
"     </li>",
"     <li>",
"      Would pediatricians be responsible for interpreting data and facilitating the development of patient management plans related to conditions of adult onset?",
"     </li>",
"     <li>",
"      At what age would children be informed of their specific liabilities?",
"     </li>",
"     <li>",
"      Should information be provided for conditions for which there is no known cure or treatment?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Standardization and oversight of testing ���",
"      </strong>",
"      As illustrated by the preliminary concordance studies of DTC genetic tests, there is considerable inconsistency in the predicted genetic risk [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. These inconsistencies are largely due to differences in the risk estimation models used and in the SNP content on the array platforms. Standardization of these models and the SNP content will help improve this problem. The US Food and Drug Administration (US FDA) is currently developing policies regarding standardization and oversight of these tests, and policies have been discussed in Australia and the United Kingdom; some have advocated for international certification of quality standards [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Reimbursement legislation ���",
"      </strong>",
"      Changes in the reimbursement policies will be needed to promote a personalized medicine initiative. Several attempts have been made to modify the Medicare clinical laboratory fee schedule to accommodate the reimbursement for complex genetic tests.",
"     </li>",
"     <li>",
"      <strong>",
"       Societal issues and misconceptions",
"      </strong>",
"      ��� Numerous societal challenges must be addressed prior to widespread implementation of genomic medicine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acceptance of genetic-based treatment recommendations may be low, particularly among minority groups where the issues of genetics and race are so intimately interrelated [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Concern that misconceptions of genetic determinism could result in a medicalization of society, whereby healthy subjects become preoccupied with disease prevention based on their profile. One study of subjects who underwent direct-to-consumer genomewide profiling found no measurable evidence for increased anxiety, comparing baseline and posttesting anxiety scores [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genome sequencing will likely identify a variety of &ldquo;high-risk&rdquo; alleles in all individuals. With limited understanding of risk concepts, the identification of &ldquo;high-risk&rdquo; alleles or recessive traits could inappropriately influence reproductive decisions.",
"     </li>",
"     <li>",
"      Individuals may be adversely impacted when advised of increased risk for sensitive issues such as psychiatric disorders or behavioral traits.",
"     </li>",
"     <li>",
"      The desirability of learning if an individual has increased risk for conditions for which there is no available treatment or prevention is questionable. In one study, more than 80 percent of at-risk individuals who had no symptoms chose not to pursue testing for Huntington disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8777/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Family dynamics might be affected by disclosure, or failure to disclose, genetic information.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H487603359\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Potential benefits of personalized medicine include customized treatment plans that could encompass targeted pharmacotherapy to improve drug response and reduce toxicity and expense, targeted recommendations for lifestyle modifications and other disease prevention strategies, and enhanced patient satisfaction with healthcare. Genetic information can enhance patient compliance with behavior modification recommendations. (See",
"      <a class=\"local\" href=\"#H2097366\">",
"       'The Personalized Health Care Initiative'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genotyping panels of selected risk variants are now available as direct-to-consumer products. There remains limited utility of such panels for common polygenic or multifactorial diseases at present. (See",
"      <a class=\"local\" href=\"#H582867830\">",
"       'Genotyping panels'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      The earliest implementation of genetic profiling into clinical practice has been in the area of pharmacogenetic testing. Pharmacogenetic biomarkers are available for over 70 drugs; many of these markers involve polymorphisms in cytochrome drug metabolizing activity. (See",
"      <a class=\"local\" href=\"#H2097456\">",
"       'Pharmacogenetic testing'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=see_link\">",
"       \"Overview of pharmacogenomics\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Genome sequencing technology is rapidly evolving to become affordable and reliable. However, significant challenges remain in the ability to interpret the sequencing data that generate multiple sequence variants, both known SNPs and novel variants, with uncertain predictive associations and clinical applicability. (See",
"      <a class=\"local\" href=\"#H2097381\">",
"       'Next-generation sequencing (exome sequencing and whole genome sequencing)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct to consumer genetic analyses are currently available, largely based on genotyping platforms. Although biomarker identification appears accurate, there is wide and discrepant variation in the interpretation of the clinical relevance of the identified markers. Additionally, the majority of variants tested provide only incremental changes in a patient&rsquo;s risk profile, beyond lifestyle, family history, and environmental factors. Clinicians are faced with uncertainty when patients provide them with these reports. (See",
"      <a class=\"local\" href=\"#H2097388\">",
"       'Direct-to-consumer testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In time, analyses based upon gene expression profiling, proteomics, metabolomics, or lipidomics may enhance the predictive value of testing used for personalized medicine. Gene expression profiling is currently used for some tumors, reflecting cellular, genetic, and environmental factors. (See",
"      <a class=\"local\" href=\"#H2097395\">",
"       'Other personalized medicine platforms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple issues will need to be addressed to successfully implement personalized medicine. Beyond the development of validated biomarkers, areas of concern include physicians&rsquo; knowledge base of genetics and risk interpretation; infrastructure to store and confidentially retrieve an individual&rsquo;s genetic data; timing of testing; issues of providence in terms of clinicians responsible for ordering and transmitting information; test standardization and quality; reimbursement; and overcoming public misperceptions related to genetic data. (See",
"      <a class=\"local\" href=\"#H2097402\">",
"       'Obstacles for implementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/1\">",
"      Li C. Personalized medicine - the promised land: are we there yet? Clin Genet 2011; 79:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/2\">",
"      Vogenberg FR, Barash CI, Pursel M. Personalized medicine: part 3: challenges facing health care plans in implementing coverage policies for pharmacogenomic and genetic testing. P T 2010; 35:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/3\">",
"      Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009; 106:9362.",
"     </a>",
"    </li>",
"    <li>",
"     President's council of advisors on science and technology. cdm266901.cdmhost.com; 2008. file://www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. www.hhs.gov. (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/6\">",
"      Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med 2007; 33:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/7\">",
"      Collins RE, Wright AJ, Marteau TM. Impact of communicating personalized genetic risk information on perceived control over the risk: a systematic review. Genet Med 2011; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/8\">",
"      Wright AJ, French DP, Weinman J, Marteau TM. Can genetic risk information enhance motivation for smoking cessation? An analogue study. Health Psychol 2006; 25:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/9\">",
"      Sanderson SC, Michie S. Genetic testing for heart disease susceptibility: potential impact on motivation to quit smoking. Clin Genet 2007; 71:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/10\">",
"      Huijgen R, Kindt I, Verhoeven SB, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One 2010; 5:e9220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/11\">",
"      Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011; 364:524.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. file://www.fda.gov (Accessed on May 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/13\">",
"      Jain KK. Applications of AmpliChip CYP450. Mol Diagn 2005; 9:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/14\">",
"      Anderson JL, Horne BD, Stevens SM, et al. A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125:1997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/15\">",
"      Lifton RP. Individual genomes on the horizon. N Engl J Med 2010; 362:1235.",
"     </a>",
"    </li>",
"    <li>",
"     23andMe Website. Available at: https://www.23andme.com/exome (Accessed on January 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/17\">",
"      Lupski JR, Reid JG, Gonzaga-Jauregui C, et al. Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med 2010; 362:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/18\">",
"      Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/19\">",
"      Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 2010; 375:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/20\">",
"      Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011; 305:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/21\">",
"      Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA 2011; 305:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/22\">",
"      Bianchi DW. From prenatal genomic diagnosis to fetal personalized medicine: progress and challenges. Nat Med 2012; 18:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/23\">",
"      Minon JM, Gerard C, Senterre JM, et al. Routine fetal RHD genotyping with maternal plasma: a four-year experience in Belgium. Transfusion 2008; 48:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/24\">",
"      Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011; 118:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/25\">",
"      Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011; 11:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/26\">",
"      Wright CF, Hall A, Zimmern RL. Regulating direct-to-consumer genetic tests: what is all the fuss about? Genet Med 2011; 13:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/27\">",
"      Zehnbauer B. Direct-to-consumer genetics testing--fair comparisons? Clin Chem 2011; 57:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/28\">",
"      Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature 2009; 461:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/29\">",
"      Imai K, Kricka LJ, Fortina P. Concordance study of 3 direct-to-consumer genetic-testing services. Clin Chem 2011; 57:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/30\">",
"      Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health and disease. Cell 2008; 134:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/31\">",
"      Gross RW, Han X. Lipidomics at the interface of structure and function in systems biology. Chem Biol 2011; 18:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/32\">",
"      Puri R, Duong M, Uno K, et al. The emerging role of plasma lipidomics in cardiovascular drug discovery. Expert Opin Drug Discov 2012; 7:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/33\">",
"      Quinn PJ, Rainteau D, Wolf C. Lipidomics of the red cell in diagnosis of human disorders. Methods Mol Biol 2009; 579:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/34\">",
"      Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/35\">",
"      Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/36\">",
"      Friedman DR, Weinberg JB, Barry WT, et al. A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res 2009; 15:6947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/37\">",
"      Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008; 299:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/38\">",
"      Walt DR, Kuhlik A, Epstein SK, et al. Lessons learned from the introduction of personalized genotyping into a medical school curriculum. Genet Med 2011; 13:63.",
"     </a>",
"    </li>",
"    <li>",
"     file://deansnewsletter.stanford.edu/archive/09_28_09.html (Accessed on September 28, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/40\">",
"      Nakamura MM, Ferris TG, DesRoches CM, Jha AK. Electronic health record adoption by children's hospitals in the United States. Arch Pediatr Adolesc Med 2010; 164:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/41\">",
"      Hing E, Hall MJ, Ashman JJ. Use of electronic medical records by ambulatory care providers: United States, 2006. Natl Health Stat Report 2010; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/42\">",
"      Hauskeller C. Direct to consumer genetic testing. BMJ 2011; 342:d2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/43\">",
"      Ormond KE, Wheeler MT, Hudgins L, et al. Challenges in the clinical application of whole-genome sequencing. Lancet 2010; 375:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/44\">",
"      Samani NJ, Tomaszewski M, Schunkert H. The personal genome--the future of personalised medicine? Lancet 2010; 375:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8777/abstract/45\">",
"      Creighton S, Almqvist EW, MacGregor D, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington's disease: the experience in Canada from 1987 to 2000. Clin Genet 2003; 63:462.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14599 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-655E7897C0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8777=[""].join("\n");
var outline_f8_36_8777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H487603359\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2097359\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2097366\">",
"      THE PERSONALIZED HEALTH CARE INITIATIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2097373\">",
"      PERSONALIZED MEDICINE TODAY: GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H582867830\">",
"      Genotyping panels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2097456\">",
"      Pharmacogenetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2097381\">",
"      Next-generation sequencing (exome sequencing and whole genome sequencing)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13119540\">",
"      Fetal personalized medicine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2097388\">",
"      Direct-to-consumer testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2097395\">",
"      OTHER PERSONALIZED MEDICINE PLATFORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2097402\">",
"      OBSTACLES FOR IMPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H487603359\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/14599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/14599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/13/29917\" title=\"table 1\">",
"      Direct-to-consumer genetic profiling services",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24602?source=related_link\">",
"      Genetic counseling and testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/21/5464?source=related_link\">",
"      Management of pregnancy complicated by Rhesus (Rh) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/32/22026?source=related_link\">",
"      Overview of pharmacogenomics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/44/10950?source=related_link\">",
"      Principles of complex trait genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39799?source=related_link\">",
"      Tools for genetics and genomics: Gene expression",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_36_8778="Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors";
var content_f8_36_8778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sex cord-stromal tumors of the ovary: Granulosa-stromal cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8778/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8778/contributors\">",
"     David M Gershenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8778/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8778/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8778/contributors\">",
"     Rochelle L Garcia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/36/8778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/36/8778/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/36/8778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian sex cord-stromal tumors are a heterogeneous group of benign or malignant tumors that develop from the dividing cell population that would normally produce cells which support and surround the oocytes, including the cells that produce ovarian hormones (the nongerm cell and nonepithelial components of the gonads) (",
"    <a class=\"graphic graphic_figure graphicRef72286 \" href=\"UTD.htm?43/17/44307\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/1\">",
"     1",
"    </a>",
"    ]. Ovarian sex cord-stromal tumors are rare, comprising only 1.2 percent of all primary ovarian cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast with epithelial ovarian cancer, most patients with malignant sex cord-stromal tumors are diagnosed with early-stage disease; the tumors are generally considered to be low-grade malignancies.",
"   </p>",
"   <p>",
"    Sex-cord stromal tumors include granulosa cell tumors (which differentiate toward female characteristics), fibroma-thecomas, and Sertoli-Leydig cell tumors (which differentiate toward male characteristics). Granulosa-stromal cell tumors include granulosa cell tumors, thecomas, and fibromas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/3\">",
"     3",
"    </a>",
"    ]. They account for 70 percent of ovarian sex cord-stromal tumors. Among granulosa-stromal cell tumors, fibromas are the most common histology. These tumors occur with equal frequency among pre- and postmenopausal women.",
"   </p>",
"   <p>",
"    Granulosa cell, theca cell, and mixed tumors are usually hormonally active, in contrast to fibromas, which do not produce hormones. Granulosa cell tumors are more often malignant than thecomas or fibromas, which are most often benign.",
"   </p>",
"   <p>",
"    Ovarian sex cord-stromal tumors of the granulosa-stromal cell type (granulosa cell tumors, fibromas, and thecomas) are reviewed here. An overview of sex cord-stromal tumors and other types of sex cord-stromal tumors of the ovary (Sertoli-stromal cell tumors and tumors with granulosa and Sertoli-Leydig elements), as well as epithelial ovarian cancer, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link\">",
"     \"Overview of sex cord-stromal tumors of the ovary\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=see_link\">",
"     \"Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=see_link\">",
"     \"Epithelial ovarian cancer: Pathology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GRANULOSA CELL TUMOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulosa cell tumors have malignant potential (ie, the ability to metastasize). They are the most common type of potentially malignant ovarian sex cord stromal tumor; they comprise two to five percent of all ovarian malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two subtypes, adult and juvenile. The adult subtype, which occurs most commonly in middle aged and older women (median age 50 to 54 years), comprises 95 percent of these neoplasms.",
"   </p>",
"   <p>",
"    The juvenile type comprises 5 percent of all granulosa cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/4\">",
"     4",
"    </a>",
"    ]. They typically develop before puberty, and thus, are more common among children and young women. This subtype tends to have a higher proliferative rate than the adult type and a lower risk for late recurrences.",
"   </p>",
"   <p>",
"    The discussion below relates mainly to the adult subtype.",
"   </p>",
"   <p>",
"    Granulosa cell tumors appear to be more common in women who are non-white, obese (body mass index &gt;30), and have a family history of breast or ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk appears to be decreased in women who are current or past smokers or users of oral contraceptive pills, and in those who are parous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gross appearance of granulosa cell tumors is variable. The neoplasms are usually large and unilateral, and can be soft or firm depending upon the relationships of stroma, particularly collagen to neoplastic cells. They are often multicystic and may resemble a mucinous cystadenoma or be filled with serous fluid or clotted blood. Accumulation of lipids results in yellow color.",
"   </p>",
"   <p>",
"    Histologically, granulosa cells of the adult subtype appear round, pale, with scant cytoplasm, and classic \"coffee-bean\" grooved nuclei; atypia and mitoses are typically not frequent but do occur (",
"    <a class=\"graphic graphic_picture graphicRef79902 \" href=\"UTD.htm?30/54/31591\">",
"     picture 1",
"    </a>",
"    ). The cells may arrange themselves in small clusters or rosettes around a central cavity. These arrangements, which are termed \"Call-Exner bodies\", resemble primordial follicles and, when diffusely present, constitute a microfollicular pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/6\">",
"     6",
"    </a>",
"    ]. Lack of Call-exner bodies is not infrequent.",
"   </p>",
"   <p>",
"    In contrast, the juvenile subtype has a macrofollicular or cystic pattern and is comprised of immature granulosa cells with frequent mitoses; Call-Exner bodies and coffee-bean grooved nuclei are not frequent.",
"   </p>",
"   <p>",
"    While the better differentiated granulosa cell tumors may have various patterns, including microfollicular, macrofollicular, trabecular, solid-trabecular, and insular, less well-differentiated tumors have a more diffuse pattern, designated as sarcomatoid. Other pattern types are diffuse, cylindroid, pseudoadenomatous, or mixed, depending upon the predominant histological elements. These various patterns are not particularly important but can render recognition as granulosa cell tumor difficult.",
"   </p>",
"   <p>",
"    Theca cells, which are luteinized cells within the stroma, are present in about 70 percent of cases. Theca cells produce androstenedione, a weak androgen, and granulosa cells convert the androstenedione to estradiol. Significant hormone production is responsible for the clinical phenotype associated with the neoplasm. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Clinical features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The histologic diagnosis is facilitated by immunohistochemical staining (IHC) using antibodies against markers of sex cord stromal differentiation. Inhibin is the most sensitive and specific [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Calretinin is typically positive but is not specific for sex cord stromal differentiation. Other markers including CD99, mullerian inhibiting substance, vimentin, WT1, SF-1, cytokeratin, S-100 protein, and smooth muscle actin are not specific and are not particularly helpful in distinguishing between granulosa cell tumor and its mimics [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. However, even positivity for inhibin is not absolutely specific for an ovarian sex cord tumor as sex cord stromal differentiation can be seen in other neoplasms. As an example, in one report, positive IHC for inhibin was present in 94 percent of granulosa cell tumors and in 10 to 20 percent of ovarian endometrioid tumors and metastatic carcinomas to the ovary (although with significantly weaker staining intensity) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the future, molecular testing for mutations in the FOXL2 gene may improve diagnostic accuracy in patients with sex cord-stromal tumors. Somatic mutations in this gene, which play a role in the development of normal granulosa cells, have been identified in 97 percent of adult-type GCTs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In contrast, the mutation was identified in only 1 of 10 juvenile-type GCTs, and 3 of 14 thecomas (21 percent), while it was absent in sex cord-stromal tumors of other types and in other ovarian neoplasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulosa cell tumors typically present as large masses; the mean diameter is 12 cm. Women may present with an asymptomatic mass noted on abdominal or pelvic examination.",
"   </p>",
"   <p>",
"    Granulosa cell tumors often produce estrogen",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progesterone; consequently, symptoms related to hyperestrogenism are common at diagnosis. In a review of 118 patients with granulosa cell tumors, 55 percent had hyperestrogenic findings, including hyperplastic endometrium and abnormal uterine bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/14\">",
"     14",
"    </a>",
"    ]. Increased production of estrogen may also cause breast tenderness, postmenopausal bleeding, menstrual abnormalities, and, in children, sexual precocity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a well-documented association between granulosa cell tumors and endometrial neoplasms (complex endometrial hyperplasia and adenocarcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/15\">",
"     15",
"    </a>",
"    ]. For this reason, as noted in a preceding section, preoperative endometrial biopsy is suggested in all women with abnormal uterine bleeding, all postmenopausal women with an adnexal mass and a thickened (&ge;5 mm) endometrial stripe, and in the occasional patient who has a preoperative diagnosis of ovarian granulosa cell tumor. Endometrial biopsy will detect endometrial",
"    <span class=\"nowrap\">",
"     hyperplasia/intraepithelial",
"    </span>",
"    neoplasia in 25 to 50 percent of women with granulosa cell tumors and carcinoma in 5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The endometrial adenocarcinomas that are associated with granulosa-stromal cell tumors are usually early stage and well differentiated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonspecific symptoms or signs associated with these neoplasms include ascites, increasing abdominal girth, or abdominal pain due to torsion, intraneoplasmal hemorrhage, or tumor rupture and hemoperitoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of a granulosa cell tumor is made by histology at the time of surgical excision. Preoperatively, a granulosa cell tumor should be suspected based upon the presence of a large adnexal mass, if accompanied by the signs of hyperestrogenism described in the preceding section. Ultrasonographic findings (an echogenic, septated cystic or solid mass related to the ovary) are typically nonspecific. Surgery is required for histologic diagnosis as well as staging (staging is the best determination of potential malignant behavior) and treatment.",
"   </p>",
"   <p>",
"    The differential diagnosis of a woman who presents with both an adnexal mass and abnormal vaginal bleeding should also include ovarian metastasis from a primary uterine cancer, an endometrial metastasis from a primary ovarian malignant neoplasm, and separate primary ovarian and endometrial carcinomas.",
"   </p>",
"   <p>",
"    The hormonal activity of granulosa cell tumors permits the use of a variety of serum tumor markers in the diagnostic evaluation (",
"    <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"     table 1",
"    </a>",
"    ). Clinically, the most useful serum marker for granulosa cell tumors is inhibin, a peptide that is produced by the ovaries in response to follicle stimulating hormone and luteinizing hormone. Inhibin usually becomes undetectable after menopause, unless produced by certain ovarian tumors, mostly mucinous epithelial ovarian carcinomas and granulosa cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/19-24\">",
"     19-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibin exists as two different isoforms, inhibin A and inhibin B. Both isoforms consist of a dimer of two subunits, the alpha and beta subunits. The alpha subunit is the same for both isoforms, while the beta subunits differ (beta A and beta B); they show about 64 percent homology. The three subunits (alpha, beta A, beta B) are produced on separate genes located on chromosomes 2 (alpha and beta B subunit) and 7 (beta A subunit). In general, both inhibin A and inhibin B should be ordered when following patients with granulosa cell tumors. However, neither marker is perfect. Both may be negative in patients with active granulosa cell tumors, but either may be helpful, particularly in helping to diagnose recurrent granulosa cell tumor. Inhibin A is elevated more frequently, but when negative, inhibin B may be elevated.",
"   </p>",
"   <p>",
"    An elevated inhibin level in a postmenopausal woman or a premenopausal woman presenting with amenorrhea and infertility is suggestive of the presence of a granulosa cell tumor, but not specific. Although most commercial laboratories only provide assays for inhibin A, serum levels of inhibin B seem to be more frequently elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/25\">",
"     25",
"    </a>",
"    ]. If available, we suggest the use of assays that detect both isoforms. The free alpha subunit can also be measured [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estradiol was one of the first markers identified in the serum of patients with granulosa cell tumors. In general, however, estradiol is not a sensitive marker for the presence of a granulosa cell tumor. Approximately 30 percent of these neoplasms do not produce estradiol, perhaps related to the lack of theca cells, which produce androstenedione, a necessary precursor for estradiol synthesis.",
"   </p>",
"   <p>",
"    M&uuml;llerian inhibiting substance (MIS), which is produced by granulosa cells in the developing follicles, has emerged as a potential tumor marker for granulosa cell tumors. As with inhibin, MIS is typically undetectable in postmenopausal women. Although an elevated MIS level appears to be highly specific for ovarian granulosa cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], this test is not available for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Surgical staging and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulosa cell tumors are staged surgically according to the FIGO ovarian cancer staging system (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 2",
"    </a>",
"    ). A total abdominal hysterectomy and bilateral salpingo-oophorectomy is recommended for women who are done with childbearing. Assessment of stage is the most important factor in determining prognosis and to guide postoperative treatment recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rarity of lymph node metastasis at initial diagnosis suggests that pelvic and paraaortic lymphadenectomy may be omitted as part of surgical staging for these neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, this is dependent upon whether an intraoperative diagnosis of a granulosa cell tumor can be made, since the diagnosis may not have been made preoperatively and is difficult to confirm during surgery.",
"   </p>",
"   <p>",
"    Granulosa cell tumors are generally confined to one ovary. For women with stage I disease who wish to preserve fertility or avoid exogenous hormone replacement, a unilateral salpingo-oophorectomy and uterine preservation with other procedures for complete surgical staging are appropriate (",
"    <a class=\"graphic graphic_table graphicRef75194 \" href=\"UTD.htm?40/8/41099\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/33\">",
"     33",
"    </a>",
"    ]. Retrospective studies suggest an equivalent cure rate for early stage disease whether treated by unilateral salpingo-oophorectomy or bilateral salpingo-oophorectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The contralateral ovary should be carefully inspected; biopsy is necessary only if an abnormality is found.",
"   </p>",
"   <p>",
"    Due to the risk of endometrial neoplasia, if an endometrial biopsy was not performed preoperatively, a dilation and curettage should be performed during surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery alone is acceptable treatment for most women with granulosa cell tumors, since the majority are stage IA and confined to one ovary at the time of diagnosis (",
"    <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/34\">",
"     34",
"    </a>",
"    ]. Long-term disease-free survival rates are approximately 90 percent.",
"   </p>",
"   <p>",
"    Outcomes are less favorable for women with higher stage disease and for those with stage I disease whose tumor has ruptured, has nuclear atypia, or a high mitotic index. There are conflicting reports regarding the prognostic influence of other factors such as positive cytology, tumor size, ovarian surface involvement, and ploidy status. Further studies are needed in this area. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Prognosis and follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although postoperative or adjuvant therapy is often considered for such patients, the rarity of these neoplasms makes it difficult to conduct well-designed randomized studies to define the value of any such strategy. As a result, the benefit of postoperative treatment for women with stage 1B-IV disease is unclear and practice is variable. Some centers recommend adjuvant therapy for all women with stage IC-IV disease, others recommend adjuvant therapy only for women with residual disease after surgery, and still others do not recommend adjuvant therapy for any stage of disease, treating only at the time of a recurrence.",
"   </p>",
"   <p>",
"    The following represents the range of findings regarding the benefit of adjuvant therapy from observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with advanced stage juvenile granulosa cell tumors, adjuvant chemotherapy appears to contribute to long-lasting complete remission, and is usually recommended for those with stage IC disease and a high mitotic index (&ge; 20 per 10 high power fields [HPF]), as well as those with more advanced stage disease [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/36-42\">",
"       36-42",
"      </a>",
"      ]. However, it is difficult to extrapolate these results to adult-type tumors, which have a different biology (ie, lower proliferative rate and greater risk of late recurrences) than the juvenile type.",
"     </li>",
"     <li>",
"      Some retrospective series of adults with granulosa cell tumor suggest that women with advanced (stage",
"      <span class=\"nowrap\">",
"       III/IV)",
"      </span>",
"      disease who receive postoperative chemotherapy have a longer progression-free interval than those who do not [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/43\">",
"       43",
"      </a>",
"      ]. However, others have failed to show that the use of chemotherapy is associated with better survival [",
"      <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/18,44,45\">",
"       18,44,45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, despite the absence of data supporting a survival benefit, some experts recommend postoperative chemotherapy for women with resected stage IC to IV disease because of the high risk of disease progression (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ) and the potential for long-term survival in women with advanced disease who receive modern platinum-based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/17,36,46-50\">",
"     17,36,46-50",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H535696\">",
"     'Metastatic or recurrent disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some reserve this recommendation for women over the age of 40 at diagnosis, who, in one early series, had a higher risk of disease recurrences compared to younger women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/51\">",
"     51",
"    </a>",
"    ]. However, other reports have failed to confirm the adverse impact of older age on outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/14,52-57\">",
"     14,52-57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from the National Comprehensive Cancer Network (NCCN) recommend platinum-based chemotherapy (or RT for limited disease, see below) in women with stage II to IV ovarian stromal tumors and that these options be \"considered\" in women with high-risk stage I disease (ie, ruptured stage IC tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used regimen is a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (BEP) (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ) as is used for testicular and ovarian germ cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=see_link\">",
"     \"Treatment of malignant germ cell tumors of the ovary\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative chemotherapy options include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (EP),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and cisplatin (CAP);",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ; or a platinum agent alone. The Gynecologic Oncology Group is currently conducting a randomized phase II trial of BEP versus the combination of paclitaxel and carboplatin for patients with newly diagnosed and chemo-naive recurrent metastatic sex cord-stromal tumors of the ovary.",
"   </p>",
"   <p>",
"    As with chemotherapy, there are no prospective randomized trials that define the value of postoperative radiation therapy. Granulosa cell tumors are radioresponsive in that radiation therapy can induce clinical responses and occasional long-term remission in patients with persistent or recurrent granulosa cell tumors (see",
"    <a class=\"local\" href=\"#H535696\">",
"     'Metastatic or recurrent disease'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In the adjuvant setting, an older retrospective series is often quoted as supporting benefit from radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/53\">",
"     53",
"    </a>",
"    ]. However, insufficient data were provided to determine whether the differences in outcome between irradiated and nonirradiated women were attributable to therapy. Several later observational series fail to show any benefit from adjuvant radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/14,48,52,54,58\">",
"     14,48,52,54,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, beyond primary surgery, there is no standard for postoperative therapy. For patients with stage IA granulosa cell tumor, surgery alone is the preferred treatment. For women with stage IC-IV disease, some groups do not recommend postoperative therapy, while others recommend platinum-based chemotherapy, most frequently BEP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/16,59\">",
"     16,59",
"    </a>",
"    ]. As noted above, NCCN guidelines recommend platinum-based chemotherapy (or RT for limited disease, see below) in women with stage II to IV ovarian stromal tumors and that these options be \"considered\" in women with high-risk stage I disease (ie, ruptured stage IC tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H535696\">",
"    <span class=\"h3\">",
"     Metastatic or recurrent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common site of recurrence is the pelvis, although the retroperitoneum and upper abdomen may be involved, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no standard approach to the management of advanced unresectable or relapsed disease. Complete resection may provide long-term disease control if the neoplasm is localized [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/57\">",
"     57",
"    </a>",
"    ], but diffuse intraabdominal disease is difficult to treat effectively.",
"   </p>",
"   <p>",
"    Radiation therapy can induce clinical responses and occasional long-term remission in women with persistent or recurrent granulosa cell tumors, particularly if the disease is surgically cytoreduced [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/17,48,60\">",
"     17,48,60",
"    </a>",
"    ]. In one review of 34 patients treated at a single center over a 40-year period with radiation alone, 3 of the 14 who were treated for measurable disease were alive without progression 10 to 21 years following treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with metastatic or suboptimally cytoreduced disease, chemotherapy regimens similar to those used for germ cell tumors (eg, BEP or PEB, (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    )) are active, producing overall response rates of 58 to 84 percent (",
"    <a class=\"graphic graphic_table graphicRef65516 \" href=\"UTD.htm?14/2/14382\">",
"     table 4",
"    </a>",
"    ) are active, producing overall response rates of 58 to 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/47,49,61\">",
"     47,49,61",
"    </a>",
"    ]. In one study, 14 of 38 patients (37 percent) undergoing second-look laparotomy following four courses of BEP had negative findings [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/47\">",
"     47",
"    </a>",
"    ]. The median survival of patients who had a complete clinical response (n = 6) was over two years.",
"   </p>",
"   <p>",
"    Unfortunately, the majority of patients with advanced disease do not have durable remissions [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/47,61\">",
"     47,61",
"    </a>",
"    ]. In a combined series of patients treated with BEP for sex cord-stromal tumors, only one of seven women with metastatic disease had a durable remission [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/61\">",
"     61",
"    </a>",
"    ]. Furthermore, treatment-related toxicity (especially from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ) may be prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other chemotherapeutic regimens with reported therapeutic efficacy include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/62\">",
"     62",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/63\">",
"     63",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (PVB or VBP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/3\">",
"     3",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , doxorubicin, plus cisplatin (CAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. None of these regimens have produced consistently better results than seen with BEP, but may be considered for second-line therapy. The value of taxanes, particularly in combination with cisplatin, is under active investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experimental data and small clinical series suggest that hormonal agents such as luteinizing hormone releasing hormone agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/41/4760?source=see_link\">",
"     leuprolide",
"    </a>",
"    ) might have been effective through the suppression of gonadotropin secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/71-75\">",
"     71-75",
"    </a>",
"    ]. However, others have failed to document efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/48,76\">",
"     48,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of recurrent disease with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    alone, progesterone alone, or a combination of the two agents occasionally yields long-term clinical responses. In one case report, a complete clinical response in a patient with recurrent granulosa cell tumor was achieved using alternating biweekly cycles of megestrol 40 mg twice daily for two weeks, alternating with two week courses of tamoxifen 10 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiangiogenic therapy also appears promising. In an early report of eight patients with GCT,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody directed against the vascular endothelial growth factor (VEGF), induced a complete clinical response in one patient, partial responses in two, and stable disease in two others [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/77\">",
"     77",
"    </a>",
"    ]. The Gynecologic Oncology Group is currently conducting a phase II trial of bevacizumab for women with recurrent sex cord-stromal ovarian tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prognosis and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of ovarian granulosa cell tumor depends upon the stage of disease at diagnosis and the presence of residual disease after surgery (",
"    <a class=\"graphic graphic_table graphicRef67595 \" href=\"UTD.htm?26/16/26891\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/17,45,58,78-80\">",
"     17,45,58,78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five-year survival rates for completely resected stage I disease are approximately 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/45,46,58\">",
"     45,46,58",
"    </a>",
"    ], but outcomes tend to be less favorable in the presence of a large tumor size (10 to 15 cm) or (in many but not all series [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/57\">",
"     57",
"    </a>",
"    ]) tumor rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/14,54,55,58,81\">",
"     14,54,55,58,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of histologic features have also been examined for their prognostic significance. In adult neoplasms, cellular atypia, high mitotic index (4 to 10 mitoses per 10 HPF), and the absence of Call-Exner bodies are the only significant histologic predictors of early recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/30,57,58\">",
"     30,57,58",
"    </a>",
"    ]. Abnormal karyotype, p53 overexpression, and ploidy do not appear to be of prognostic value [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian granulosa cell tumors have metastatic potential and a tendency for late relapse. In one report of 37 women with stage I disease, survival rates at 5, 10, and 20 years were 94, 82, and 62 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/46\">",
"     46",
"    </a>",
"    ]. The median time to relapse is approximately four to six years after initial diagnosis; however, late recurrences have been reported after as many as 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/14,30,46,58,84,85\">",
"     14,30,46,58,84,85",
"    </a>",
"    ]. Thus, prolonged surveillance with serial physical examinations and serum tumor markers (particularly inhibin) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/33\">",
"     33",
"    </a>",
"    ] should be performed.",
"   </p>",
"   <p>",
"    After primary therapy, prolonged surveillance with serial physical examinations and serum tumor marker levels is indicated because of the indolent growth pattern of these neoplasms. There is no consensus on the frequency of postoperative surveillance. In general, we follow patients with pelvic examinations and serum inhibin levels every three months for the first two years, every four to six months during years three to five, and yearly thereafter since recurrences can occur many years after initial diagnosis. In addition, following serum estradiol levels postoperatively may be useful for detecting recurrence of an estradiol-secreting neoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/3,14\">",
"     3,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic imaging studies such as computed tomography (CT) or chest radiographs are performed only if clinically indicated (eg, evaluation of specific symptoms or an elevated inhibin level), but are not recommended for routine follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/17,86\">",
"     17,86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of posttreatment surveillance for sex cord-stromal tumors can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=see_link&amp;anchor=H4401872#H4401872\">",
"     \"Overview of sex cord-stromal tumors of the ovary\", section on 'Posttreatment surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     FIBROMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromas are the most common of the sex-cord stromal tumors. Pure fibromas are benign solid neoplasms, usually unilateral, that primarily occur in postmenopausal women. They are not hormonally active.",
"   </p>",
"   <p>",
"    Cellular fibromas are characterized by mildly increased cellular density, mild nuclear atypia, and an average of three or fewer mitotic figures per 10 HPF. In contrast, fibrosarcomas (which have four or more mitotic figures per 10 HPF plus marked cellular density and nuclear atypia) are very rare malignant ovarian sarcomas whose aggressiveness correlates with the number of mitoses and the degree of anaplasia.",
"   </p>",
"   <p>",
"    On ultrasound examination, an ovarian fibroma may appear as a mass that is either hyper- or hypoechoic, which may be calcified",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exhibit cystic degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/87\">",
"     87",
"    </a>",
"    ]. Ascites is present in 10 to 15 percent of cases and hydrothorax in 1 percent, especially with larger lesions.",
"   </p>",
"   <p>",
"    The association of ovarian fibroma with ascites",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural effusion is termed Meigs' syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/88\">",
"     88",
"    </a>",
"    ]. Fluid accumulation is probably related to substances like vascular endothelial growth factor (VEGF) that raise capillary permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/21,85\">",
"     21,85",
"    </a>",
"    ]. Removal of the neoplasm results in elimination of ascites and pleural effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/89\">",
"     89",
"    </a>",
"    ]. Several cases of Meigs' syndrome have been reported in association with an elevated serum CA 125 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, neither ascites or pleural effusion, nor an elevated CA 125 is necessarily indicative of an advanced epithelial ovarian carcinoma in a woman with a pelvic mass.",
"   </p>",
"   <p>",
"    Pseudo-Meigs' syndrome (a clinical syndrome of pleural effusion, ascites, and an ovarian mass that is not a fibroma or fibroma-like",
"    <span class=\"nowrap\">",
"     mass/tumor)",
"    </span>",
"    has been reported from a number of sources, such as leiomyomas, struma ovarii, mucinous cystadenoma, teratoma, and malignancies that are metastatic to the ovary (particularly colorectal cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian fibromas associated with basal cell cancers are called nevoid basal cell carcinoma syndrome or Gorlin's syndrome. Other associated findings include odontogenic keratocysts, brain neoplasms, and mesenteric cysts. Gorlin's syndrome is inherited as an autosomal dominant trait with high degree of penetrance (97 percent) but variable expressivity. Whether the inherited germline abnormality responsible for Gorlin's syndrome (a mutation in the patched or PTCH1 gene on chromosome 9) is related to the development of ovarian fibromas as well is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=see_link\">",
"     \"Nevoid basal cell carcinoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common treatment for an ovarian fibroma is unilateral salpingo-oophorectomy. For women who desire preservation of the ovary, an ovarian cystectomy may be performed with complete excision of the fibromatous tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     THECOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thecomas are solid, fibromatous neoplasms and are generally benign. They are composed of theca cells and arise from the ovarian stroma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/93\">",
"     93",
"    </a>",
"    ]. Thecomas are almost exclusively confined to one ovary and occur predominantly in postmenopausal women (average age 59 years). Thecomas may produce estrogen and up to 20 percent of patients present with a synchronous endometrial cancer.",
"   </p>",
"   <p>",
"    Grossly, they have a yellowish appearance from accumulated lipids (also seen in granulosa cell tumors) and can become very large (up to 40 cm). Histologically, they are primarily composed of theca cells, but may also contain granulosa cell components. The tumors are designated granulosa-theca cell tumors or granulosa cell tumors depending upon the relative amount of granulosa versus theca cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/78\">",
"     78",
"    </a>",
"    ]. Malignant thecomas are rare, and may be interpreted as fibrosarcomas or a diffuse form of a granulosa cell tumor.",
"   </p>",
"   <p>",
"    The most common symptom of thecomas is abnormal uterine bleeding as a result of endometrial stimulation from estrogen produced by theca cells. Endometrial hyperplasia and carcinoma are present in approximately 15 and 25 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/20\">",
"     20",
"    </a>",
"    ]. Ascites is rare. Ultrasound generally reveals a nonspecific ovarian mass.",
"   </p>",
"   <p>",
"    We suggest that treatment of thecomas in women in the menopausal transition and postmenopausal women include a TAH-BSO. This recommendation takes into account the possible presence of a synchronous endometrial malignancy, as well as the rare occurrence of ovarian fibrosarcoma, a malignant mixed M&uuml;llerian neoplasm of the uterus, or endometrial stromal sarcoma.",
"   </p>",
"   <p>",
"    Unilateral oophorectomy is an option in young women when preservation of fertility or avoidance of exogenous hormone replacement is desired [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All women with a thecoma should have pre- or intraoperative endometrial sampling to exclude the presence of a synchronous endometrial malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22494399\">",
"    <span class=\"h1\">",
"     FIBROTHECOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term fibrothecoma is used by some experts to refer to a neoplasm with features that are intermediate between a fibroma and a thecoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/94\">",
"     94",
"    </a>",
"    ]. There is no universal agreement on which neoplasms should be classified as a fibrothecoma rather than either a fibroma or thecoma; however, many neoplasms have mixtures of these cell types.",
"   </p>",
"   <p>",
"    Hormonal activity of these neoplasms depends upon the extent to which they resemble fibromas (lipid-poor, hormonally inert) or thecomas (lipid-containing, hormonally active) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Fibrothecomas may be either benign or malignant, although they are most commonly benign [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. The risk of malignancy is difficult to predict due to inconsistent classification and the paucity of data regarding these neoplasms. Of note, women with a significant amount of hormonally active thecoma elements are at risk for endometrial neoplasia, similar to pure thecomas. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Thecoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Pelvic imaging can certainly narrow the differential diagnosis of an adnexal mass, but there is nothing pathognomonic about the ultrasound or magnetic resonance imaging (MRI) appearance of fibrothecomas. Typically, they appear as a solid ovarian mass and are considered worrisome for malignant neoplasm. The sonographic appearance of these neoplasms is usually nonspecific. On MRI, fibrothecomas typically have low signal intensity on T1-weighted images and very low signal intensity on T2-weighted images [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/98-100\">",
"     98-100",
"    </a>",
"    ]. Large fibrothecomas may have areas of edema and cystic degeneration. However, there is one report indicating that dual-echo chemical shift MRI may be a useful method for detecting small amounts of lipid in thecomas versus the fibrous tissue in fibromas [",
"    <a class=\"abstract\" href=\"UTD.htm?8/36/8778/abstract/101\">",
"     101",
"    </a>",
"    ]. But once again, stromal tumors may contain both thecoma elements and fibroma elements (hence \"fibrothecoma\"), so this distinction is probably of very limited clinical benefit.",
"   </p>",
"   <p>",
"    Ultimately, regardless of imaging findings, removal of the mass is required, since these lesions are neoplastic. The diagnosis is made based upon histology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Granulosa cell tumor",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulosa cell tumors are generally large and unilateral and have malignant potential. They are categorized into two subtypes, adult and juvenile. The adult subtype is more common and occurs mostly in middle aged and older women, while the juvenile subtype occurs mostly in children and young women. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These neoplasms often produce estrogen (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 1",
"      </a>",
"      ). Granulosa cell tumors typically present as a large adnexal mass frequently with signs of hyperestrogenism (abnormal uterine bleeding, endometrial neoplasia, breast tenderness, and, in children, precocious puberty). We recommend endometrial sampling pre- or intraoperatively to exclude asymptomatic endometrial neoplasm (carcinoma or its precursor) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical staging and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest total abdominal hysterectomy and bilateral salpingo-oophorectomy for women with granulosa cell tumors who have completed childbearing (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For women with stage I disease (",
"      <a class=\"graphic graphic_table graphicRef51205 \" href=\"UTD.htm?14/43/15038\">",
"       table 2",
"      </a>",
"      ) who wish to preserve childbearing capacity or avoid estrogen therapy, we suggest unilateral oophorectomy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical staging and treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest a course of postoperative platinum-based chemotherapy for all women with resected stage IC to IV disease because of the high risk of disease progression and the potential for long-term survival in women with advanced disease who receive modern platinum-based chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, others disagree, either recommending chemotherapy only for women who are left with measurable residual disease following surgery, or withholding adjuvant chemotherapy for all women regardless of stage, and treating only at the time of recurrence. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Adjuvant therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For recurrent localized disease, we suggest surgical resection, if feasible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest chemotherapy rather than surgery alone for patients with metastatic or suboptimally cytoreduced disease (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Radiation may be appropriate as primary treatment or as an adjunctive therapy following surgery in selected patients with recurrence confined to the pelvis. (See",
"      <a class=\"local\" href=\"#H535696\">",
"       'Metastatic or recurrent disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After primary therapy, prolonged surveillance with serial physical examinations and serum tumor marker levels (if elevated, (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 1",
"      </a>",
"      )) is indicated because of the indolent growth pattern of these neoplasms. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prognosis and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fibroma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibromas are the most common of the sex-cord stromal tumors. Pure fibromas are benign solid usually unilateral neoplasms that primarily occur in postmenopausal women. They are not hormonally active.",
"     </li>",
"     <li>",
"      Fibromas are rarely associated with Meigs' syndrome (ie, ovarian fibroma, ascites, pleural effusion).",
"     </li>",
"     <li>",
"      We recommend oophorectomy for diagnosis and cure for women with ovarian fibromas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Fibroma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Thecoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thecomas are usually benign neoplasms; like granulosa cell tumors, thecomas may produce estrogen (",
"      <a class=\"graphic graphic_table graphicRef55817 \" href=\"UTD.htm?24/4/24653\">",
"       table 1",
"      </a>",
"      ) and usually present as abnormal uterine bleeding in a postmenopausal woman.",
"     </li>",
"     <li>",
"      We suggest unilateral oophorectomy and endometrial sampling for women with thecomas who have not completed childbearing or wish to avoid exogenous hormone replacement (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest total abdominal hysterectomy with bilateral salpingo-oophorectomy for all other women (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Thecoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2055242\">",
"    <span class=\"h2\">",
"     Fibrothecoma",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term fibrothecoma is used by some experts to refer to a neoplasm with features that are intermediate between a fibroma and a thecoma. Hormonal activity of these neoplasms depends upon the extent to which they resemble fibromas (lipid-poor, hormonally inert) or thecomas (lipid-containing, hormonally active). Fibrothecomas are usually benign. (See",
"      <a class=\"local\" href=\"#H22494399\">",
"       'Fibrothecoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/1\">",
"      Young RH. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol 2005; 18 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/2\">",
"      Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol 2005; 97:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/3\">",
"      Segal R, DePetrillo AD, Thomas G. Clinical review of adult granulosa cell tumors of the ovary. Gynecol Oncol 1995; 56:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/4\">",
"      Lack EE, Perez-Atayde AR, Murthy AS, et al. Granulosa theca cell tumors in premenarchal girls: a clinical and pathologic study of ten cases. Cancer 1981; 48:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/5\">",
"      Boyce EA, Costaggini I, Vitonis A, et al. The epidemiology of ovarian granulosa cell tumors: a case-control study. Gynecol Oncol 2009; 115:221.",
"     </a>",
"    </li>",
"    <li>",
"     Young R, Clement PB, Scully RE. The ovary. In: Surgical Pathology, Sternberg SS (Ed), Raven Press, New York 1989. p.1687.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/7\">",
"      McCluggage WG. Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. J Clin Pathol 2000; 53:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/8\">",
"      Movahedi-Lankarani S, Kurman RJ. Calretinin, a more sensitive but less specific marker than alpha-inhibin for ovarian sex cord-stromal neoplasms: an immunohistochemical study of 215 cases. Am J Surg Pathol 2002; 26:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/9\">",
"      Matias-Guiu X, Pons C, Prat J. M&uuml;llerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol 1998; 29:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/10\">",
"      Hildebrandt RH, Rouse RV, Longacre TA. Value of inhibin in the identification of granulosa cell tumors of the ovary. Hum Pathol 1997; 28:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/11\">",
"      Zhao C, Vinh TN, McManus K, et al. Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol 2009; 33:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/12\">",
"      Shah SP, K&ouml;bel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med 2009; 360:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/13\">",
"      K&ouml;bel M, Gilks CB, Huntsman DG. Adult-type granulosa cell tumors and FOXL2 mutation. Cancer Res 2009; 69:9160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/14\">",
"      Evans AT 3rd, Gaffey TA, Malkasian GD Jr, Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol 1980; 55:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/15\">",
"      Adamian RT. [Hyperplastic processes and endometrial cancer in patients with hormone-producing ovarian tumors]. Vopr Onkol 1991; 37:48.",
"     </a>",
"    </li>",
"    <li>",
"     Berek JS, Hacker NF. Nonepithelial ovarian and fallopian tube cancers. In: Practical Gynecologic Oncology, 3rd, Berek JS, Hacker NF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.539.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/17\">",
"      Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/18\">",
"      Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol 2004; 25:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/19\">",
"      Lapp&ouml;hn RE, Burger HG, Bouma J, et al. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989; 321:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/20\">",
"      Jobling T, Mamers P, Healy DL, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 1994; 55:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/21\">",
"      Boggess JF, Soules MR, Goff BA, et al. Serum inhibin and disease status in women with ovarian granulosa cell tumors. Gynecol Oncol 1997; 64:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/22\">",
"      Healy DL, Burger HG, Mamers P, et al. Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 1993; 329:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/23\">",
"      Gustafson ML, Lee MM, Scully RE, et al. M&uuml;llerian inhibiting substance as a marker for ovarian sex-cord tumor. N Engl J Med 1992; 326:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/24\">",
"      Robertson DM, Stephenson T, Pruysers E, et al. Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer. J Clin Endocrinol Metab 2002; 87:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/25\">",
"      Mom CH, Engelen MJ, Willemse PH, et al. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 2007; 105:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/26\">",
"      Robertson DM, Stephenson T, Pruysers E, et al. Inhibins/activins as diagnostic markers for ovarian cancer. Mol Cell Endocrinol 2002; 191:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/27\">",
"      Rey RA, Lhomm&eacute; C, Marcillac I, et al. Antim&uuml;llerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol 1996; 174:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/28\">",
"      Lane AH, Lee MM, Fuller AF Jr, et al. Diagnostic utility of M&uuml;llerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999; 73:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/29\">",
"      Chang HL, Pahlavan N, Halpern EF, MacLaughlin DT. Serum M&uuml;llerian Inhibiting Substance/anti-M&uuml;llerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol 2009; 114:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/30\">",
"      Miller BE, Barron BA, Wan JY, et al. Prognostic factors in adult granulosa cell tumor of the ovary. Cancer 1997; 79:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/31\">",
"      Brown J, Sood AK, Deavers MT, et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/32\">",
"      Abu-Rustum NR, Restivo A, Ivy J, et al. Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol 2006; 103:31.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/34\">",
"      Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994; 55:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/35\">",
"      Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol 2007; 104:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/36\">",
"      Schneider DT, Calaminus G, Wessalowski R, et al. Ovarian sex cord-stromal tumors in children and adolescents. J Clin Oncol 2003; 21:2357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/37\">",
"      Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/38\">",
"      Young RH, Dickersin GR, Scully RE. Juvenile granulosa cell tumor of the ovary. A clinicopathological analysis of 125 cases. Am J Surg Pathol 1984; 8:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/39\">",
"      Calaminus G, Wessalowski R, Harms D, G&ouml;bel U. Juvenile granulosa cell tumors of the ovary in children and adolescents: results from 33 patients registered in a prospective cooperative study. Gynecol Oncol 1997; 65:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/40\">",
"      Schneider DT, Calaminus G, Wessalowski R, et al. Therapy of advanced ovarian juvenile granulosa cell tumors. Klin Padiatr 2002; 214:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/41\">",
"      Schneider DT, J&auml;nig U, Calaminus G, et al. Ovarian sex cord-stromal tumors--a clinicopathological study of 72 cases from the Kiel Pediatric Tumor Registry. Virchows Arch 2003; 443:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/42\">",
"      Plantaz D, Flamant F, Vassal G, et al. [Granulosa cell tumors of the ovary in children and adolescents. Multicenter retrospective study in 40 patients aged 7 months to 22 years]. Arch Fr Pediatr 1992; 49:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/43\">",
"      Uygun K, Aydiner A, Saip P, et al. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary. Gynecol Oncol 2003; 88:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/44\">",
"      Al-Badawi IA, Brasher PM, Ghatage P, et al. Postoperative chemotherapy in advanced ovarian granulosa cell tumors. Int J Gynecol Cancer 2002; 12:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/45\">",
"      Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol 2005; 96:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/46\">",
"      Lauszus FF, Petersen AC, Greisen J, Jakobsen A. Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease. Gynecol Oncol 2001; 81:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/47\">",
"      Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 1999; 72:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/48\">",
"      Savage P, Constenla D, Fisher C, et al. Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol) 1998; 10:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/49\">",
"      Colombo N, Sessa C, Landoni F, et al. Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary. Obstet Gynecol 1986; 67:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/50\">",
"      Zambetti M, Escobedo A, Pilotti S, De Palo G. cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary. Gynecol Oncol 1990; 36:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/51\">",
"      Schwartz PE, Smith JP. Treatment of ovarian stromal tumors. Am J Obstet Gynecol 1976; 125:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/52\">",
"      Ohel G, Kaneti H, Schenker JG. Granulosa cell tumors in Israel: a study of 172 cases. Gynecol Oncol 1983; 15:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/53\">",
"      Pankratz E, Boyes DA, White GW, et al. Granulosa cell tumors. A clinical review of 61 cases. Obstet Gynecol 1978; 52:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/54\">",
"      Bj&ouml;rkholm E, Silfversw&auml;rd C. Prognostic factors in granulosa-cell tumors. Gynecol Oncol 1981; 11:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/55\">",
"      Stenwig JT, Hazekamp JT, Beecham JB. Granulosa cell tumors of the ovary. A clinicopathological study of 118 cases with long-term follow-up. Gynecol Oncol 1979; 7:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/56\">",
"      Fox H, Agrawal K, Langley FA. A clinicopathologic study of 92 cases of granulosa cell tumor of the ovary with special reference to the factors influencing prognosis. Cancer 1975; 35:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/57\">",
"      Sehouli J, Drescher FS, Mustea A, et al. Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 2004; 24:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/58\">",
"      Malmstr&ouml;m H, H&ouml;gberg T, Risberg B, Simonsen E. Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 1994; 52:50.",
"     </a>",
"    </li>",
"    <li>",
"     Gershenson DM, Hartmann LC, Young RH. Ovarian sex cord-stromal tumors. In: Principles and Practice of Gynecologic Oncology, WJ, Young RC, Markman M, Perez CA, Barakat R, Randall M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.1011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/60\">",
"      Wolf JK, Mullen J, Eifel PJ, et al. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol 1999; 73:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/61\">",
"      Gershenson DM, Morris M, Burke TW, et al. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin. Obstet Gynecol 1996; 87:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/62\">",
"      Disaia P, Saltz A, Kagan AR, Rich W. A temporary response of recurrent granulosa cell tumor to adriamycin. Obstet Gynecol 1978; 52:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/63\">",
"      Powell JL, Otis CN. Management of advanced juvenile granulosa cell tumor of the ovary. Gynecol Oncol 1997; 64:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/64\">",
"      Muntz HG, Goff BA, Fuller AF Jr. Recurrent ovarian granulosa cell tumor: role of combination chemotherapy with report of a long-term response to a cyclophosphamide, doxorubicin and cisplatin regimen. Eur J Gynaecol Oncol 1990; 11:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/65\">",
"      Gershenson DM, Copeland LJ, Kavanagh JJ, et al. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide. Obstet Gynecol 1987; 70:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/66\">",
"      Pectasides D, Alevizakos N, Athanassiou AE. Cisplatin-containing regimen in advanced or recurrent granulosa cell tumours of the ovary. Ann Oncol 1992; 3:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/67\">",
"      Tresukosol D, Kudelka AP, Edwards CL, et al. Recurrent ovarian granulosa cell tumor: a case report of a dramatic response to Taxol. Int J Gynecol Cancer 1995; 5:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/68\">",
"      Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004; 22:3517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/69\">",
"      Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 2005; 97:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/70\">",
"      Powell JL, Connor GP, Henderson GS. Management of recurrent juvenile granulosa cell tumor of the ovary. Gynecol Oncol 2001; 81:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/71\">",
"      Emons G, Schally AV. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994; 9:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/72\">",
"      Martikainen H, Penttinen J, Huhtaniemi I, Kauppila A. Gonadotropin-releasing hormone agonist analog therapy effective in ovarian granulosa cell malignancy. Gynecol Oncol 1989; 35:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/73\">",
"      Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. J Reprod Med 1996; 41:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/74\">",
"      Briasoulis E, Karavasilis V, Pavlidis N. Megestrol activity in recurrent adult type granulosa cell tumour of the ovary. Ann Oncol 1997; 8:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/75\">",
"      Hardy RD, Bell JG, Nicely CJ, Reid GC. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 2005; 96:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/76\">",
"      Maxwell GL, Soisson AP, Miles P. Failure of gonadotropin releasing hormone therapy in patients with metastatic ovarian sex cord stromal tumors. Oncology 1994; 51:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/77\">",
"      Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009; 114:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/78\">",
"      Cronj&eacute; HS, Niemand I, Bam RH, Woodruff JD. Review of the granulosa-theca cell tumors from the emil Novak ovarian tumor registry. Am J Obstet Gynecol 1999; 180:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/79\">",
"      Uygun K, Aydiner A, Saip P, et al. Granulosa cell tumor of the ovary: retrospective analysis of 45 cases. Am J Clin Oncol 2003; 26:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/80\">",
"      Lee YK, Park NH, Kim JW, et al. Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 2008; 18:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/81\">",
"      Auranen A, Sundstr&ouml;m J, Ij&auml;s J, Gr&eacute;nman S. Prognostic factors of ovarian granulosa cell tumor: a study of 35 patients and review of the literature. Int J Gynecol Cancer 2007; 17:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/82\">",
"      Ala-Fossi SL, M&auml;enp&auml;&auml; J, Aine R, et al. Prognostic significance of p53 expression in ovarian granulosa cell tumors. Gynecol Oncol 1997; 66:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/83\">",
"      Roush GR, el-Naggar AK, Abdul-Karim FW. Granulosa cell tumor of ovary: a clinicopathologic and flow cytometric DNA analysis. Gynecol Oncol 1995; 56:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/84\">",
"      Crew KD, Cohen MH, Smith DH, et al. Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature. Gynecol Oncol 2005; 96:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/85\">",
"      Ishiko O, Yoshida H, Sumi T, et al. Vascular endothelial growth factor levels in pleural and peritoneal fluid in Meigs' syndrome. Eur J Obstet Gynecol Reprod Biol 2001; 98:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/86\">",
"      Stuart GC, Dawson LM. Update on granulosa cell tumours of the ovary. Curr Opin Obstet Gynecol 2003; 15:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/87\">",
"      Chechia A, Attia L, Temime RB, et al. Incidence, clinical analysis, and management of ovarian fibromas and fibrothecomas. Am J Obstet Gynecol 2008; 199:473.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/88\">",
"      Brun JL. Demons syndrome revisited: a review of the literature. Gynecol Oncol 2007; 105:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/89\">",
"      MEIGS JV. Fibroma of the ovary with ascites and hydrothorax; Meigs' syndrome. Am J Obstet Gynecol 1954; 67:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/90\">",
"      Timmerman D, Moerman P, Vergote I. Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature. Gynecol Oncol 1995; 59:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/91\">",
"      Peparini N, Chirletti P. Ovarian malignancies with cytologically negative pleural and peritoneal effusions: demons' or meigs' pseudo-syndromes? Int J Surg Pathol 2009; 17:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/92\">",
"      Tsuji T, Catasus L, Prat J. Is loss of heterozygosity at 9q22.3 (PTCH gene) and 19p13.3 (STK11 gene) involved in the pathogenesis of ovarian stromal tumors? Hum Pathol 2005; 36:792.",
"     </a>",
"    </li>",
"    <li>",
"     DiSaia PJ, Creasman WT. Germ cell, stromal and other ovarian tumors. In: Clinical Gynecologic Oncology, 7th, Mosby-Elsevier, 2007. p.387.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/94\">",
"      Roth LM, Czernobilsky B. Perspectives on pure ovarian stromal neoplasms and tumor-like proliferations of the ovarian stroma. Am J Surg Pathol 2011; 35:e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/95\">",
"      Nowak M, Podciechowski L, Krawczyk T, Wilczynski J. Meigs' syndrome and virilizing ovarian fibrothecoma complicating pregnancy. A case report and review of the literature. Neuro Endocrinol Lett 2009; 30:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/96\">",
"      Elghorori MR, Al-Taher H, Redwood NF. Ovarian fibrothecoma: a benign neoplasm with potential adverse consequences. J Obstet Gynaecol 2003; 23:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/97\">",
"      Liu H, Hao SH, Li WM. Giant malignant ovarian fibrothecoma involved with retroperitoneal structures mimicking a retroperitoneal sarcoma. Arch Gynecol Obstet 2009; 279:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/98\">",
"      Troiano RN, Lazzarini KM, Scoutt LM, et al. Fibroma and fibrothecoma of the ovary: MR imaging findings. Radiology 1997; 204:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/99\">",
"      Jung SE, Rha SE, Lee JM, et al. CT and MRI findings of sex cord-stromal tumor of the ovary. AJR Am J Roentgenol 2005; 185:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/100\">",
"      Tanaka YO, Saida TS, Minami R, et al. MR findings of ovarian tumors with hormonal activity, with emphasis on tumors other than sex cord-stromal tumors. Eur J Radiol 2007; 62:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/36/8778/abstract/101\">",
"      Okajima Y, Matsuo Y, Tamura A, et al. Intracellular lipid in ovarian thecomas detected by dual-echo chemical shift magnetic resonance imaging: report of 2 cases. J Comput Assist Tomogr 2010; 34:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3234 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-B869A8C837-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8778=[""].join("\n");
var outline_f8_36_8778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GRANULOSA CELL TUMOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Surgical staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H535696\">",
"      - Metastatic or recurrent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prognosis and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      FIBROMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      THECOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22494399\">",
"      FIBROTHECOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Granulosa cell tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Thecoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2055242\">",
"      Fibrothecoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3234\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3234|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/17/44307\" title=\"figure 1\">",
"      Origins ovarian tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3234|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/54/31591\" title=\"picture 1\">",
"      Granulosa cell tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3234|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/4/24653\" title=\"table 1\">",
"      Ovarian tumor markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15038\" title=\"table 2\">",
"      Staging ovarian peritoneal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41099\" title=\"table 3\">",
"      Steps in staging ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/2/14382\" title=\"table 4\">",
"      Bleomycin etoposide and cisplatin regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/16/26891\" title=\"table 5\">",
"      Ovar granulosa cell tumor progn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17224?source=related_link\">",
"      Epithelial ovarian cancer: Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44121?source=related_link\">",
"      Nevoid basal cell carcinoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16087?source=related_link\">",
"      Overview of sex cord-stromal tumors of the ovary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/22/12646?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Sertoli-stromal cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32916?source=related_link\">",
"      Sex cord-stromal tumors of the ovary: Tumors with granulosa and Sertoli-Leydig elements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33162?source=related_link\">",
"      Treatment of malignant germ cell tumors of the ovary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_36_8779="Fisher SAH CT grading scale";
var content_f8_36_8779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Fisher grade of cerebral vasospasm risk in subarachnoid hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Appearance of blood on head CT scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        No blood detected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Diffuse deposition or thin layer with all vertical layers (in interhemispheric fissure, insular cistern, ambient cistern) less than 1 mm thick",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Localized clot and/or vertical layers 1 mm or more in thickness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Intracerebral or intraventricular clot with diffuse or no subarachnoid blood",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Fisher, CM, Kistler, JP, Davis, JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by CT scanning. Neurosurgery 1980; 6:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8779=[""].join("\n");
var outline_f8_36_8779=null;
var title_f8_36_8780="Infection related reproductive hazards in the workplace";
var content_f8_36_8780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disease causing agents that are reproductive hazards for women in the workplace",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Observed effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potentially exposed workers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preventative measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalo- virus (CMV)",
"       </td>",
"       <td>",
"        Birth defects, low birth weight, developmental disorders",
"       </td>",
"       <td>",
"        Health care workers, workers in contact with infants and children",
"       </td>",
"       <td>",
"        Good hygienic practices such as handwashing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B virus",
"       </td>",
"       <td>",
"        Low birth weight",
"       </td>",
"       <td>",
"        Health care workers",
"       </td>",
"       <td>",
"        Vaccination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human immuno-deficiency virus (HIV)",
"       </td>",
"       <td>",
"        Low birth weight, childhood cancer",
"       </td>",
"       <td>",
"        Health care workers",
"       </td>",
"       <td>",
"        Practice universal precautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human parvovirus B19",
"       </td>",
"       <td>",
"        Miscarriage",
"       </td>",
"       <td>",
"        Health care workers, workers in contact with infants and children",
"       </td>",
"       <td>",
"        Good hygienic practices such as handwashing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rubella (German measles)",
"       </td>",
"       <td>",
"        Birth defects, low birth weight",
"       </td>",
"       <td>",
"        Health care workers, workers in contact with infants and children",
"       </td>",
"       <td>",
"        Vaccination before pregnancy if no prior immunity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxoplasmosis",
"       </td>",
"       <td>",
"        Miscarriage, birth defects, developmental disorders",
"       </td>",
"       <td>",
"        Animal care workers, veterinarians",
"       </td>",
"       <td>",
"        Good hygiene practices such as handwashing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Varicella-zoster virus (chicken pox)",
"       </td>",
"       <td>",
"        Birth defects, low birth weight",
"       </td>",
"       <td>",
"        Health care workers, workers in contact with infants and children",
"       </td>",
"       <td>",
"        Vaccination before pregnancy if no prior immunity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     National Institute for Occupational Safety and Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8780=[""].join("\n");
var outline_f8_36_8780=null;
var title_f8_36_8781="Course of MGUS";
var content_f8_36_8781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Incidence of progression of monoclonal gammopathy of undetermined significance (MGUS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 303px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Incidence of progression in 241 patients with monoclonal gammopathy of undetermined significance (MGUS) to a monoclonal disease. The time is from the time of recognition of the monoclonal protein, and the monoclonal diseases include multiple myeloma, macroglobulinemia, amyloidosis, or lymphoproliferative disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kyle, RA, Baillieres Clin Hematol 1995; 8:761.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8781=[""].join("\n");
var outline_f8_36_8781=null;
var title_f8_36_8782="Retinoblastoma less than 8yrs";
var content_f8_36_8782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unilateral and bilateral retinoblastoma age-specific incidence rates, all races both sexes, SEER, 1976-84 and 1986-94",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 438px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Young JL, Smith MA, Roffers SD, et al. Retinoblastoma. In: Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith MA Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD, 1999. p. 73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8782=[""].join("\n");
var outline_f8_36_8782=null;
var title_f8_36_8783="Astigmatism";
var content_f8_36_8783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/61074/astigmat_conv.mp4?title=Astigmatism\" style=\"width:336px;height:226px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Astigmatism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 208px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Astigmatism is due to abnormal curvature of the cornea which results in multiple focus points in front of or behind the retina. This results in blurry distance and near vision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: the University of Michigan Kellogg Eye Center, file://www.kellogg.umich.edu.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_36_8783=[""].join("\n");
var outline_f8_36_8783=null;
